

SECTOR CAPITAL FUNDS PLC

*(A company incorporated with limited liability as an open-ended umbrella investment company
with variable capital under the laws of Ireland)*

ANNUAL REPORT AND AUDITED FINANCIAL STATEMENTS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2023

Registration No. 489443

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

TABLE OF CONTENTS

	Page
Directors' Report.....	3
Depository's Report	6
Investment Manager's Report.....	7
Independent Auditors' Report	9
Balance Sheet	11
Profit and Loss Account	13
Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares	15
Schedule of Investments	15
Notes to the Financial Statements.....	20
Significant Portfolio Movements (Unaudited).....	43
Remuneration Information (Unaudited)	45
Additional disclosures in respect of The Sustainable Finance Disclosure Regulation ("SFDR") (Unaudited).....	51

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

GENERAL INFORMATION

Directors

Michael Boyce (*Irish*)^
Lars Tell (*Swedish*)
Conor Walsh (*Irish*)^

^Independent non-executive Director

Manager

Sector Fund Services AS
Kristian Augusts gate 15 C
N-0164 Oslo
Norway

Investment Manager

Sector Healthcare Value Fund
Sector Gamma AS
Kristian Augusts gate 15 c
N-0164 Oslo
Norway

Investment Manager

Sector Emerging Markets Equity Fund
Capricorn Fund Managers Limited
Malta House
36-38 Piccadilly, London
United Kingdom W1J0DP

Administrator, Registrar and Transfer Agent

BNY Mellon Fund Services (Ireland) Designated Activity
Company
Riverside Two
Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland

Depository

The Bank of New York Mellon SA/NV, Dublin Branch
Riverside Two
Sir John Rogerson's Quay
Grand Canal Dock
Dublin 2
Ireland

Registered Office

32 Molesworth Street
Dublin 2
Ireland

Independent Auditors

Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House
Earlsfort Terrace
Dublin 2
Ireland

Legal Advisers to the Company (*advisers as to Norwegian law*)

BAHR
Advokatfirmaet BAHR AS
Tjuvholmen allé 16
NO-0252 Oslo
Norway

Legal Advisers to the Company (*advisers as to Irish law*)

Maples and Calder (Ireland) LLP
75 St. Stephen's Green
Dublin 2
Ireland

Global Distributor

Sector Capital AS
Kristian Augusts gate 15 c
N-0164 Oslo
Norway

Company Secretary

MFD Secretaries Limited
32 Molesworth Street
Dublin 2
Ireland

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

DIRECTORS' REPORT

The Directors present to the shareholders their annual report and the audited financial statements of Sector Capital Funds plc (the "Company") for the financial year 1 January 2023 to 31 December 2023.

Principal Activities and Review of Business

The Company was incorporated and registered in Ireland under the Companies Act 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010 with registered number 489443. The net assets of the Company were USD490,201,887 on 31 December 2023 (31 December 2022: USD533,513,347).

The Company was authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended) and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (as amended) (the "Regulations").

As at 31 December 2023, the Company has two funds in existence (31 December 2022: one), Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund.

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023. The base currency of Sector Emerging Markets Equities Fund is USD. As at 31 December 2023 three classes are subscribed to in the Fund, three classes are subscribed to in the Fund, Class S GBP Shares, Class S NOK Shares and Class S USD Shares.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is United States Dollars ("USD"). As at 31 December 2023, fourteen classes are subscribed to in the Fund (31 December 2022: fourteen), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B EUR Shares, Class B NOK Shares, Class B SEK Shares, Class B USD Shares, Class X USD Shares, Class X EUR Shares, Class Y EUR Shares, Class Y GBP Shares, Class Y USD Shares, Class E NOK and Class E USD.

Results, Activities and Future Developments

The results of operations are set out on page 14. A detailed review of the business and future developments for the Funds is contained in the Investment Manager's Report on page 7.

Statement of Directors' Responsibilities

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with the Companies Act 2014 and the applicable Regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law, the Directors have elected to prepare the financial statements in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland ("relevant financial reporting framework"). Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date and of the profit or loss of the Company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies for the Company financial statements and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

DIRECTORS' REPORT (Continued)

Statement of Directors' Responsibilities (Continued)

The Directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the Company, enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Audit Information Statement

So far as each of the Directors in office at the date of approval of the financial statements are aware:

- there is no relevant audit information of which the Company's auditors are unaware; and
- the Directors have taken all the steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of Section 330 of the Companies Act 2014.

Accounting Records

The Directors believe that they have complied with the requirements of Section 281 to 285 of the Companies Act 2014 with regard to the accounting records by employing the resources of an administrator, BNY Mellon Fund Services (Ireland) Designated Activity Company (the "Administrator"). During the financial year the accounting records of the Company were maintained at the offices of the Administrator, BNY Mellon Fund Services (Ireland) Designated Activity Company, Riverside Two, Sir John Rogerson's Quay, Grand Canal Dock, Dublin 2.

Fair Value Directive

It is the opinion of the Board of Directors that the information required by the European Communities (Fair Value Accounting) Regulations 2004, in relation to the use by the Company of financial instruments and the financial risk management objectives and policies of the Company and the exposures of the Company to market risk, currency risk, interest rate risk, liquidity risk and credit risk is contained in the Investment Manager's Report and note 7.

Significant events during the financial year

On 13 April 2023, a supplement was noted by the Central Bank of Ireland for the new sub-fund Sector Emerging Markets Equities Fund, which launched on 1 September 2023.

There were no other significant events during the financial year.

Significant events after the balance sheet date

There were no significant events after the balance sheet date.

Business Continuity Planning

All relevant third party service providers, including the Investment Manager, have confirmed to the Board they have applied their contingency plans to ensure operational continuity in line with regulatory obligations of the Company. No operational disturbances have been identified as of now.

Directors

Michael Boyce
Lars Tell
Conor Walsh

Directors' and Secretary's Interests

The Directors and Secretary and their families had no interest in the shares of the Company at 31 December 2023, other than as disclosed below:

As at 31 December 2023, Lars Tell, Director of the Company held 374 Class A NOK shares in Sector Healthcare Value Fund (31 December 2022: 348 Class A NOK).

Dividends

Under the Articles of Association dividends may be paid out of the profits. During the financial years ended 31 December 2023 and 31 December 2022, no dividends were paid.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

DIRECTORS' REPORT (Continued)

Corporate Governance Statement

The Company is subject to and complies with the Regulations.

The Board has adopted the voluntary Irish Funds ("IF") Corporate Governance Code for Irish domiciled Collective Investment Schemes and Management Companies, issued 14 December 2011 (the "Code") with effect from 11 December 2012. The Board has reviewed and assessed the measures included in the Code and considers its corporate governance practices and procedures since the adoption of the Code as consistent therewith.

The Company is subject to corporate governance practices imposed by:

1. The Irish Companies Acts 2014 and the Regulations which are available for inspection at the registered office of the Company and may also be obtained at www.irishstatutebook.ie.
2. The Articles of Association of the Company which are available for inspection at the registered office of the Company and at the Companies Registration Office in Ireland.
3. The Central Bank of Ireland in their Regulations which can be obtained from the Central Bank of Ireland's website at: www.centralbank.ie and are available for inspection at the registered office of the Company.

Decision not to establish an Audit Committee

The Directors have decided not to establish an audit committee pursuant to section 167(2) (b) of the Companies Act 2014. This has been decided on the basis of the following:

- a) the nature, scale and complexity of the Company's business range of services and activities undertaken in the course of that business;
- b) the resources available to the Company and the resources and expertise of the various third parties engaged to support the Company and carry out certain functions on its behalf; and
- c) the procedures in place for the review, approval and circulation of the audited financial accounts and statements which are appropriate for a self-managed investment company pursuant to the Regulations.

Independent Auditors

Deloitte Ireland LLP, Chartered Accountants and Statutory Audit Firm, have expressed their willingness to continue in office in accordance with Section 383(2) of the Companies Act 2014.

On behalf of the Board of Directors

DocuSigned by:

Lars Tell

2FC0C2AAE8AB4FC...

Lars Tell, Director

Date: 27 March 2024

DocuSigned by:

Conor Walsh

00A8A95D07E74E3...

Conor Walsh, Director

**REPORT FROM THE DEPOSITARY TO THE SHAREHOLDERS
DATED 27 MARCH 2024**

For the period from 01 January 2023 to 31 December 2023 (the “**Period**”)

The Bank of New York Mellon SA/NV, Dublin Branch (the “**Depository**” “**us**”, “**we**”, or “**our**”) has enquired into the conduct of Sector Capital Funds plc (the “**Company**”) for the Period, in its capacity as Depository to the Company.

This report including the opinion has been prepared for and solely for the shareholders in the Company, in accordance with our role as Depository to the Company and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown.

Responsibilities of the Depository

Our duties and responsibilities are outlined in Regulation 34 of the of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (S.I. No 352 of 2011), as amended (the “**Regulations**”).

Our report shall state whether, in our opinion, the Company has been managed in that period in accordance with the provisions of the Company’s constitutional documentation and the Regulations. It is the overall responsibility of the Company to comply with these provisions. If the Company has not been so managed, we as Depository must state in what respects it has not been so managed and the steps which we have taken in respect thereof.

Basis of Depository Opinion

The Depository conducts such reviews as it, in its reasonable opinion, considers necessary in order to comply with its duties and to ensure that, in all material respects, the Company has been managed (i) in accordance with the limitations imposed on its investment and borrowing powers by the provisions of its constitutional documentation and the appropriate regulations and (ii) otherwise in accordance with the Company’s constitutional documentation and the appropriate regulations.

Opinion

In our opinion, the Company has been managed during the Period, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Company by the constitutional documentation and the Regulations; and
- (ii) otherwise in accordance with the provisions of the constitutional documentation and the Regulations.

Saskia Van Goethert

For and on Behalf of
The Bank of New York Mellon SA/NV, Dublin Branch,
Riverside II,
Sir John Rogerson’s Quay,
Grand Canal Dock,
Dublin 2
Date: 27 March 2024

Registered in Ireland No. 907126, VAT No. IE9578054E

The Bank of New York Mellon SA/NV, trading as The Bank of New York Mellon SA/NV, Dublin Branch is authorised by the National Bank of Belgium.

The Bank of New York Mellon SA/NV, Boulevard Anspachlaan 1, B-1000 Brussels Belgium – Tel. (32) 2 545 81 11, V.A.T. BE 0806.743.159-RPM-RPR Brussels Company No. 0806.743.159. The Bank of New York Mellon SA/NV is a Belgian limited liability company, authorized and regulated as a significant credit institution by the European Central Bank and the National Bank of Belgium under the Single Supervisory Mechanism and by the Belgian Financial Services and Markets Authority.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

INVESTMENT MANAGER'S REPORT

Sector Emerging Markets Equities Fund

Portfolio

The Sector Emerging Markets Equities Fund (Class S USD) returned 0.1% since launch on 1st September 2023 through to the year-end, which was approximately 5% behind of the benchmark MSCI EM (TR) Index (the “EM Index”). It is important to note that around 2% of the underperformance (but zero absolute performance) was due to the Fund launching into a rapidly rising market, wherein investment could not be made until cash had cleared in the Fund, despite appearing in the NAV. This is a one-off negative luck effect at launch, but there is no client loss as there was zero return. Remaining underperformance has been more than reversed by time of writing in late January.

Geopolitics continued to cloud Emerging Market (“EM”) sentiment, whilst the Chinese economic recovery post COVID somewhat disappointed in the near term as the consumer remained cautious and export markets in the US and Europe have weakened.

Our Indian holdings, with an average weight of 39% of the Fund (the EM index has 15% Indian weighting for context), added significant gains – the weighted average return of the portfolio stocks was +24% in US dollar terms over the 4-month period (vs +14% for Indian index and +5% for the EM index) – leading contributors included several of our largest holdings – Varun Beverages and CDSL amongst them. Almost all Indian holdings have shown very strong profit momentum and were strong performance drivers for the full year.

Chinese stocks led the underperformers despite our reduced position. Sentiment to Chinese stocks was weakened due to a combination of weak macro and the splintered geopolitics from the US and others. EV battery supply chain companies, including CATL and Shenzhen Kedali, were negative contributors as the EV market cooled – although we had previously reduced positions as we see lower growth in EV’s in the near term, before a reacceleration in the global EV market from 2026 onwards. The Chinese EV battery market has slowed, but still grew at 33% in kWh terms year-on-year for 2023 with the last few months broadly growing at a similar rate. CATL has been retained and the position recently increased as it is the low-cost producer globally with leading technology and resilient profit growth, trading at a significant discount to intrinsic value. Samsung SDI, a Korean battery company, was sold as the Chinese are in a stronger competitive position for the future.

In 2023 the market has broadly been a “value” market and hence unsuited to the long-term Cusana GEM strategy style – and yet we have outperformed from the launch to time of writing in late January, and overall delivered a respectable positive return in real terms dollar terms despite difficult geopolitics that led to Chinese stocks being the victims of outflow, even if posting robust fundamental performance.

Most importantly, when the Fed pivoted towards a loosening monetary bias in late October 2023, and market sentiment turned towards long duration stocks in the last two months of the year, the Fund and the strategy generally have responded very positively - and we started to outperform as we had expected.

Macro developments

We launched the Fund with a lower aggregate position in China than we would normally expect, in recognition of the increasing geopolitical friction between the US and China. We see little risk of a Taiwan invasion but more risk of US market intervention into the ability of certain US investors to own Chinese stocks, given the state of US politics. We weigh this market effect against compelling fundamental stock opportunities in China, and we will still invest selectively where we see great opportunities.

We could happily fill our portfolio with Indian ideas with a 5-year view and the current portfolio exposure is over 40%, largely in consumer-oriented businesses. We see strong profit momentum in many (but by no means all) Indian industries. A capital investment cycle is accelerating, including housing, though valuations are quite demanding in some areas given the relatively low compounding potential (due to low ROIC) that many capital-intensive companies provide. We still find better risk versus reward in capital-light consumer-oriented sectors that benefit from the consumption upgrade and high sustained growth in companies with wide economic moats. Such businesses also tend to have reduced risk profiles despite stronger long term return potential.

Whilst many Indian stocks continue to deliver, we do see excesses in more fashionable parts of the market, such as in housebuilders and electronics manufacturers – and so we prefer to play a patient game in identifying the best balance of risk versus reward with a 5-year view.

Other opportunities have been seized in the best ASEAN economies, namely Indonesia and Vietnam. Indonesia is well positioned, along with Vietnam, for taking some manufacturing export share from China, but also for its domestic consumer growth. Both economies have had a subdued patch that has presented great opportunities in high quality companies. Vietnam, in particular, had a short sharp credit cycle from which it is now emerging. ASEAN markets are tight on liquidity, so we have a material advantage, given our size, to provide clients with meaningful positions in mid-caps where the growth potential is highest, which is much more attractive than being constrained to the largest banks, as is the case with peers running \$5bn+ AUM.

Outlook

We continue to expect US and European recessions but hopefully they will be mild. A weaker dollar and prospects of a lower cost of money are very positive for the EM consumer, particularly in less indebted and well managed countries in Asia, such as India, Vietnam and Indonesia. Our cautious view on Western economies is reflected in our ownership only of companies that are not dependent on Western economic strength. Even previously laggard EM’s, such as Brazil, should benefit from falling cost of capital as inflation has fallen rapidly and most EM’s never saw the degree of inflation spike of the Western economies with unorthodox monetary policies through COVID, as visible in money supply growth figures.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

INVESTMENT MANAGER'S REPORT (Continued)

Sector Emerging Markets Equities Fund Continued)

Global inflation is broadly back under control on the back of rapid tightening of Western monetary policy and in turn leads to a very different investment backdrop that is far more favourable for EM consumer economies. We seek country exposures with robust fiscal, debt and demographic positions and with strong institutional frameworks that will support sustained growth over the next 5 years and beyond. India ranks first, followed by Indonesia and Vietnam and Mexico some way behind these.

Western economies are slowing rapidly as higher cost of debt bites with a lag, whilst EM's broadly avoided the profligate policy that led to the surge in inflation and consequent hangover. US and other bond yields have now started falling since late October 2023 after a previous rapid rise. That EM bonds have outperformed DM bonds by a large margin over the last year is unsurprising as they did not face the same inflationary challenges so could turn the corner more quickly when real yields became too high. This is usually a lead indicator for better performance from EM equities and currencies.

Lower bond yields and stronger currencies are particularly favourable for the longer duration growth opportunities that this strategy favours with its 5-year valuation horizon. The best growth opportunities in the world over the next 5 years are, in our opinion, in places like India with such high internal growth potential. The pressure to defend currencies is reducing as the US dollar falls and, in conjunction with responsible monetary policies in recent years, the outlook for EM and for our consumer discretionary oriented portfolio is very positive.

We are delighted the strategy performance has kept up with the market over the last three years despite the EM "value" index materially outperforming EM "growth" by nearly 30% over the period. But now the strategy is well poised to take advantage of market conditions that we have been anticipating and positioning for over the last 12 months, and that are more favourable for longer duration growth stocks. The strategy is designed to optimise value capture from the great EM compounding opportunities that we can identify over the next 5 years and more.

Cusana Capital LLP
January 2024

Sector Healthcare Value Fund

The broad equity markets¹ rallied 23.8% higher in 2023, led by a recovery in the technology sector and growth stocks more broadly. Energy stocks as well as defensive sectors, including healthcare stocks, sharply under-performed. The healthcare sector returned 3.8 percent in 2023, experiencing its weakest relative return year since 1999. On a two-year return basis, sector trends are more balanced with the healthcare sector being down 1.9% and the broader markets being up 1.3%. Artificial intelligence, obesity therapeutic progress and interest rate volatility dominated news-flow in 2023. The healthcare index was heavily influenced by the strong bull market in a select few large-cap obesity driven companies both in 2023 and 2022. Medtech stocks were the best performing healthcare sub-sector in 2023, driven by strong healthcare utilisation trends and positive pipeline progress. The life sciences tool and diagnostics sector were the weakest sub-sector in 2023, driven by weaker end markets partly related to the COVID-19 unwind.

The Sector Healthcare Value Fund rose 1.6% in 2023 in what we experienced as a challenging stock picking environment for our contrarian value driven approach. The Fund struggled in the third quarter, coinciding with a selloff in mid-cap stocks and with mega-cap growth stocks rising in value. For the large part, we believe the fundamental news flow of the portfolio was a net positive in 2023. Three long holdings were targets of M&A, we had more wins than losses on earnings revisions and the portfolio had some significant pipeline and patent wins in 2023. The top contributing holdings were Cardinal Health, GSK, Seagen and Tenet healthcare. The position in Novartis and their Sandoz spin off were also solid contributors. The worst performing holdings were Bristol Myers, Incyte and Eisai. On a relative basis, the Fund underperformed by 2.1 percent in 2023 but is 1.9% ahead of index on a two-year basis. Not owning Eli Lilly and Novo Nordisk was unusually costly, on a relative basis, both in 2023 and in 2022.

The fundamental outlook for the healthcare sector continues to be attractive. This positive fundamental outlook is only reflected in a small selection of very large healthcare growth stocks. We believe a diversified approach towards fundamentally sound and undervalued healthcare companies, across both large and mid-cap stocks, will be profitable going forward. Broader macro, regulatory and funding environment uncertainties are biggest challenges as we enter 2024. The forward P/E multiple of the current portfolio are at 10-year lows, and we are optimistic about the stock picking opportunity set going into 2023.

Sector Gamma AS
January 2024

¹ MSCI World USD

² MSCI World Healthcare USD

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

Report on the audit of the financial statements

Opinion on the financial statements of Sector Capital Funds Plc ("the company")

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2023 and of the result for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework, the applicable Regulations and, in particular, with the requirements of the Companies Act 2014.

The financial statements we have audited comprise:

- the Balance Sheet;
- the Profit and Loss Account;
- the Statement of Changes in Net Assets attributable to holders of Redeemable Participating Shares;
- the Schedule of Investments; and
- the related notes 1 to 23, including a summary of significant accounting policies as set out in note 2.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' issued by the Financial Reporting Council ("the relevant financial reporting framework").

The applicable regulations that have been applied in their preparation is the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 ("the applicable Regulations").

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "*Auditor's responsibilities for the audit of the financial statements*" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Continued on next page/

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

Other information

The other information comprises the information included in the Annual Report and Audited Financial Statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Annual Report and Audited Financial Statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on IAASA's website at: <https://iaasa.ie/publications/description-of-the-auditors-responsibilities-for-the-audit-of-the-financial-statements>. This description forms part of our auditor's report.

Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not

Continued on next page/

/Continued from previous page

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF SECTOR CAPITAL FUNDS PLC

identified material misstatements in the directors' report.

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

Use of our report

This report is made solely to the company's shareholders, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's shareholders as a body, for our audit work, for this report, or for the opinions we have formed.



Christian Macmanus
For and on behalf of Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House, 29 Earlsfort Terrace, Dublin 2

28 March 2024

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

BALANCE SHEET

As at 31 December 2023

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Current Assets				
Investments in financial assets held at fair value through profit or loss		17,136,467	474,110,320	491,246,787
Cash at bank and brokers	6	2,523,984	–	2,523,984
Interest receivable		282	62,794	63,076
Dividends receivable		8,672	795,422	804,094
Other assets		188,396	601	188,997
Total Assets		19,857,801	474,969,137	494,826,938
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss		9,140	879,841	888,981
Bank overdraft		–	1,266,539	1,266,539
Payable for securities purchased		158,472	–	158,472
Payable to investment manager	9	29,076	349,003	378,079
Incentive fee/performance fee	10	–	158,518	158,518
Administration fee	11	20,376	202,606	222,982
Directors' fees and expenses	12	243	9,369	9,612
Auditors' fee	13	8,063	8,063	16,125
Depository/Custodian fee	11	10,109	26,800	36,909
Legal fee		–	2,607	2,607
Interest payable		3,541	–	3,541
Equalisation credit payable		–	1,211,186	1,211,186
Trading and Research fees		2,781	4,170	6,951
Other creditors		150,861	113,687	264,548
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		392,662	4,232,389	4,625,051
Net assets attributable to holders of Redeemable Participating Shares	20	19,465,139	470,736,748	490,201,887

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023.

On behalf of the Board of Directors

DocuSigned by:

Lars Tell

2FC0C2AAE8AB4FC...

Lars Tell, Director

Date: 27 March 2024

DocuSigned by:

Conor Walsh

60A8A95D67E74E3...

Conor Walsh, Director

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

BALANCE SHEET (Continued)

As at 31 December 2022

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Current Assets				
Investments in financial assets held at fair value through profit or loss		–	538,316,153	538,316,153
Interest receivable		–	62,618	62,618
Dividends receivable		–	874,312	874,312
Other assets		–	918	918
Total Assets		–	539,254,001	539,254,001
Current Liabilities				
Investments in financial liabilities held at fair value through profit or loss		–	744,646	744,646
Bank overdraft	6	–	1,283,950	1,283,950
Subscriptions received in advance		–	410,000	410,000
Payable to investment manager	9	–	453,956	453,956
Incentive fee/performance fee	10	–	243,401	243,401
Administration fee	11	–	425,459	425,459
Directors' fees and expenses	12	–	9,233	9,233
Auditors' fee	13	–	15,705	15,705
Depository/Custodian fee	11	–	57,346	57,346
Legal fee		–	63,231	63,231
Equalisation credit payable		–	1,936,258	1,936,258
Trading and Research fees		–	2,560	2,560
Other creditors		–	94,909	94,909
Total Liabilities (excluding net assets attributable to holders of Redeemable Participating Shares)		–	5,740,654	5,740,654
Net assets attributable to holders of Redeemable Participating Shares	20	–	533,513,347	533,513,347

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

PROFIT AND LOSS ACCOUNT

For the financial year ended 31 December 2023

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Income				
Dividend income		60,188	9,089,141	9,149,329
Interest income		11,843	758,776	770,619
Other income		37,487	59,205	96,692
		<u>109,518</u>	<u>9,907,122</u>	<u>10,016,640</u>
Net realised gain/(loss) on:				
- investments		(467,833)	15,502,570	15,034,737
- foreign currency		(46,710)	(13,173,261)	(13,219,971)
Net change in unrealised appreciation/(depreciation) on:				
- investments		1,187,050	(20,040,834)	(18,853,784)
- foreign currency		146,926	13,253,659	13,400,585
Net investment gain		<u>928,951</u>	<u>5,449,256</u>	<u>6,378,207</u>
Expenses				
Management fee	9	(29,076)	(4,596,427)	(4,625,503)
Incentive fee/performance fee	10	—	9,471	9,471
Administration fee	11	(20,376)	(546,015)	(566,391)
Depository/Custodian fee	11	(30,328)	(188,196)	(218,524)
Directors' fees and expenses	12	(464)	(39,217)	(39,681)
Auditors' fee		(9,411)	(9,411)	(18,822)
Legal fee		(623)	(39,666)	(40,289)
Trading and research fees		(5,285)	(172,013)	(177,298)
Other expenses		(20,595)	(199,001)	(219,596)
Total expenses		<u>(116,158)</u>	<u>(5,780,475)</u>	<u>(5,896,633)</u>
Net gain/(loss) before finance costs		<u>812,793</u>	<u>(331,219)</u>	<u>481,574</u>
Finance costs				
Interest expense		(12,640)	(3,286)	(15,926)
Total finance costs		<u>(12,640)</u>	<u>(3,286)</u>	<u>(15,926)</u>
Taxation				
Withholding tax and other taxation		(186,652)	(1,658,016)	(1,844,668)
Net increase/(decrease) in net assets attributable to holders of Redeemable Participating Shares resulting from operations		<u>613,501</u>	<u>(1,992,521)</u>	<u>(1,379,020)</u>

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023.

There are no recognised gains or losses for the year other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

PROFIT AND LOSS ACCOUNT (Continued)

For the financial year ended 31 December 2022

	Note	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Income				
Dividend income		–	10,065,742	10,065,742
Interest income		–	276,940	276,940
Other income		–	16,491	16,491
		–	10,359,173	10,359,173
Net realised gain/(loss) on:				
- investments		–	5,757,079	5,757,079
- foreign currency		–	(21,901,824)	(21,901,824)
Net change in unrealised appreciation/(depreciation) on:				
- investments		–	(986,236)	(986,236)
- foreign currency		–	(6,339,840)	(6,339,840)
Net investment loss		–	(13,111,648)	(13,111,648)
Expenses				
Management fee	9	–	(4,689,054)	(4,689,054)
Incentive fee/performance fee	10	–	(51,233)	(51,233)
Administration fee	11	–	(550,183)	(550,183)
Depository/Custodian fee	11	–	(179,091)	(179,091)
Directors' fees and expenses	12	–	(35,313)	(35,313)
Auditors' fee	13	–	(17,812)	(17,812)
Legal fee		–	(120,487)	(120,487)
Trading and research fees		–	(155,537)	(155,537)
Other expenses		–	(172,502)	(172,502)
Total expenses		–	(5,971,212)	(5,971,212)
Net (loss) before finance costs		–	(19,082,860)	(19,082,860)
Finance costs				
Interest expense		–	(5,940)	(5,940)
Total finance costs		–	(5,940)	(5,940)
Taxation				
Withholding tax and other taxation		–	(1,928,266)	(1,928,266)
Net decrease in net assets attributable to holders of Redeemable Participating Shares resulting from operations		–	(21,017,066)	(21,017,066)

There are no recognised gains or losses for the year other than those set out in the Profit and Loss Account. All activities relate to continuing operations.

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES

For the financial year ended 31 December 2023

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial year	–	533,513,347	533,513,347
Capital transactions:			
Issue of Redeemable Participating Shares	23,881,449	102,036,469	125,917,918
Redemption of Redeemable Participating Shares	(5,029,811)	(162,882,998)	(167,912,809)
Equalisation applied	–	62,451	62,451
Net increase/(decrease) in net assets resulting from capital transactions of Redeemable Participating Shares	18,851,638	(60,784,078)	(41,932,440)
Net increase/(decrease) in net assets attributable to holders of Redeemable Participating Shares resulting from operations	613,501	(1,992,521)	(1,379,020)
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial year	19,465,139	470,736,748	490,201,887

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023.

For the financial year ended 31 December 2022

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD	Sector Capital Funds Plc USD
Net Assets attributable to holders of Redeemable Participating Shares at beginning of the financial year	–	480,884,750	480,884,750
Capital transactions:			
Issue of Redeemable Participating Shares	–	160,584,846	160,584,846
Redemption of Redeemable Participating Shares	–	(86,346,965)	(86,346,965)
Equalisation applied	–	(592,218)	(592,218)
Net increase in net assets resulting from capital transactions of Redeemable Participating Shares	–	73,645,663	73,645,663
Net decrease in net assets attributable to holders of Redeemable Participating Shares resulting from operations	–	(21,017,066)	(21,017,066)
Net Assets attributable to holders of Redeemable Participating Shares at end of the financial year	–	533,513,347	533,513,347

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

STATEMENT OF NET ASSETS ATTRIBUTABLE TO HOLDERS OF REDEEMABLE PARTICIPATING SHARES

As at 31 December 2023

Sector Emerging Markets Equities Fund

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss</u>			
<u>Equities</u>			
<u>Canada</u>			
Sigma Lithium Corp.	6,200	1.00%	195,486
Total Canada		1.00%	195,486
<u>Cayman Islands</u>			
NU Holdings Ltd.	96,700	4.14%	805,511
Sea Ltd.	7,400	1.54%	299,700
Total Cayman Islands		5.68%	1,105,211
<u>China</u>			
BYD Co. Ltd.	20,500	2.89%	562,870
Contemporary Amperex Technology Co. Ltd.	21,600	2.56%	497,225
Total China		5.45%	1,060,095
<u>India</u>			
Central Depository Services Ltd.	46,752	5.27%	1,025,003
Cholamandalam Investment and Finance Co. Ltd.	56,883	4.42%	861,170
Computer Age Management Services Ltd.	17,095	2.80%	544,690
Devyani International Ltd.	279,545	3.34%	650,876
Jubilant FoodWorks Ltd.	111,615	3.89%	757,904
SBI Cards & Payment Services Ltd.	90,736	4.26%	828,320
Sonata Software Ltd.	86,990	3.99%	776,456
Titan Co. Ltd.	20,016	4.54%	884,082
Varun Beverages Ltd.	107,628	8.22%	1,599,797
Total India		40.73%	7,928,298
<u>Indonesia</u>			
Indofood CBP Sukses	1,002,600	3.54%	688,608
PT Bank Central Asia Tbk	1,546,300	4.85%	944,029
Total Indonesia		8.39%	1,632,637
<u>Jersey</u>			
Arcadium Lithium Plc	39,407	1.55%	301,430
Total Jersey		1.55%	301,430
<u>Korea, Republic Of</u>			
Samsung SDI Co., Ltd.	793	1.49%	290,625
Total Korea, Republic Of		1.49%	290,625
<u>Mexico</u>			
Walmart de México y Centroamérica	136,400	2.96%	576,465
Total Mexico		2.96%	576,465
<u>Netherlands</u>			
ASML Holding N.V.	751	2.91%	565,533
Total Netherlands		2.91%	565,533
<u>South Africa</u>			
Gold Fields Ltd.	28,100	2.09%	406,326
Total South Africa		2.09%	406,326
<u>Switzerland</u>			
Cie Financiere Richemont SA	1,547	1.12%	217,203
Total Switzerland		1.12%	217,203

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

SCHEDULE OF INVESTMENTS (Continued)

As at 31 December 2023

Sector Emerging Markets Equities Fund

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss</u>			
Equities			
<u>Taiwan</u>			
Taiwan Semiconductor Manufacturing Co. Ltd.	61,000	6.05%	1,178,638
Total Taiwan		6.05%	1,178,638
<u>Thailand</u>			
Mega Lifesciences PCL	197,000	1.19%	232,308
Total Thailand		1.19%	232,308
<u>United States</u>			
Broadcom, Inc.	600	3.44%	669,750
Nvidia Corp.	1,500	3.82%	742,830
Total United States		7.26%	1,412,580
Total Equities		87.87%	17,102,835
Contracts-for-Difference			
<u>Vietnam</u>			
Mobile World Investment Corp.	96,100	0.09%	17,007
Phu Nhuan Jewelry JSC	98,400	0.08%	16,625
Total Vietnam		0.17%	33,632
Total Contracts-for-Difference		0.17%	33,632
Total Financial Assets at Fair Value through profit or loss		88.04%	17,136,467
<u>Financial Liabilities at Fair Value through profit or loss</u>			
Contracts-for-Difference			
<u>China</u>			
Proya Cosmetics Co. Ltd.	18,600	(0.05)%	(9,140)
Total Contracts-for-Difference		(0.05)%	(9,140)
Total Financial Liabilities at Fair Value through profit or loss		(0.05)%	(9,140)
Total Investments at Fair Value		87.99%	17,127,327
Cash at bank and brokers		12.97%	2,523,984
Liabilities in excess of other assets		(0.96)%	(186,172)
Total Net Assets		100.00%	19,465,139

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS AND CONTRACTS-FOR-DIFFERENCE WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange listing or traded on a regulated market	86.18%
Financial derivative instruments	0.14%
Other assets	13.68%
Total Assets	100.00%

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

SCHEDULE OF INVESTMENTS (Continued)

As at 31 December 2023

Sector Healthcare Value Fund

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss</u>			
<u>Equities</u>			
<u>Belgium</u>			
UCB S.A.	152,533	2.82%	13,294,301
Total Belgium		2.82%	13,294,301
<u>Denmark</u>			
H Lundbeck A/S	1,850,000	1.91%	8,980,862
Total Denmark		1.91%	8,980,862
<u>France</u>			
BioMerieux	96,347	2.27%	10,706,829
Sanofi	173,660	3.66%	17,218,977
Total France		5.93%	27,925,806
<u>Ireland</u>			
Alkermes Plc	137,929	0.81%	3,826,150
Medtronic Plc	298,640	5.23%	24,601,963
Total Ireland		6.04%	28,428,113
<u>Japan</u>			
Astellas Pharma, Inc.	662,388	1.68%	7,921,593
Eisai Co. Ltd.	220,633	2.34%	11,036,345
Otsuka Holdings Co. Ltd.	385,131	3.07%	14,448,559
Sysmex Corp.	64,658	0.77%	3,603,933
Total Japan		7.86%	37,010,430
<u>Netherlands</u>			
Qiagen NV	130,832	1.21%	5,682,034
Total Netherlands		1.21%	5,682,034
<u>Sweden</u>			
Biovitrum AB	146,555	0.83%	3,882,791
Total Sweden		0.83%	3,882,791
<u>Switzerland</u>			
Novartis AG	162,390	3.48%	16,375,025
Roche Holding AG	37,915	2.34%	11,014,338
Sandoz Group AG	351,173	2.40%	11,290,609
Total Switzerland		8.22%	38,679,972
<u>United Kingdom</u>			
GSK PLC	1,858,926	7.30%	34,366,243
Smith & Nephew Plc	560,650	1.64%	7,708,219
Total United Kingdom		8.94%	42,074,462
<u>United States</u>			
Abbott Laboratories	39,876	0.93%	4,389,151
Acadia Pharmaceuticals, Inc.	127,627	0.85%	3,996,001
Alnylam Pharmaceuticals, Inc.	22,937	0.93%	4,390,371
Anthem, Inc.	22,271	2.23%	10,502,113
Baxter International, Inc.	224,327	1.84%	8,672,482
Biogen, Inc.	69,449	3.82%	17,971,318
BioMarin Pharmaceutical, Inc.	52,632	1.08%	5,074,778
Bio-Rad Laboratories, Inc.	16,957	1.16%	5,475,246
Bristol-Myers Squibb Co.	284,708	3.10%	14,608,368
Bruker Corp.	89,988	1.40%	6,612,318

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

SCHEDULE OF INVESTMENTS (Continued)

As at 31 December 2023

Sector Healthcare Value Fund (continued)

<i>Investment</i>	Units/Contracts	Fair Value as a % of Net Assets	Fair Value USD
<u>Financial Assets at Fair Value through profit or loss</u>			
<u>Equities</u>			
<u>United States</u>			
Cardinal Health, Inc.	114,422	2.45%	11,533,738
Centene Corp.	144,177	2.27%	10,699,375
CVS Health Corp.	154,874	2.60%	12,228,851
Edwards Lifesciences Corp.	129,120	2.09%	9,845,400
GE HealthCare	172,792	2.84%	13,360,277
Gilead Sciences, Inc.	270,582	4.66%	21,919,848
Globus Medical, Inc.	148,367	1.68%	7,906,477
Illumina, Inc.	24,957	0.74%	3,475,013
Incyte Corp. Ltd.	274,236	3.66%	17,219,278
Ionis Pharmaceuticals, Inc.	95,756	1.03%	4,844,296
Laboratory Corporations of America Holdings	34,546	1.67%	7,851,960
Lantheus Holdings, Inc.	31,712	0.42%	1,966,144
Pfizer, Inc.	738,556	4.52%	21,263,027
Tenet Healthcare Corp.	129,719	2.08%	9,802,865
Ultragenyx Pharmaceutical, Inc.	64,178	0.65%	3,068,992
Vir Biotechnology, Inc.	82,470	0.18%	829,648
Zimmer Biomet Holdings, Inc.	98,848	2.55%	12,029,802
Total United States		53.43%	251,537,137
Total Equities		97.19%	457,495,908
<u>Money Market Funds</u>			
Goldman Sachs US\$ Treasury Liquid Reserves Fund	12,217,186	2.60%	12,217,186
Total Money Market Funds		2.60%	12,217,186
Net unrealised gain on forward foreign currency contracts (Note 7)		0.95%	4,397,226
Total Financial Assets at Fair Value through profit or loss		100.74%	474,110,320
<u>Financial Liabilities at Fair Value through profit or loss</u>			
Net unrealised loss on forward foreign currency contracts (Note 7)		(0.21)%	(879,841)
Total Financial Liabilities at Fair Value through profit or loss		(0.21)%	(879,841)
Total Investments at Fair Value		100.53%	473,230,479
Cash at bank and brokers		(0.27)%	(1,266,539)
Liabilities in excess of other assets		(0.26)%	(1,227,192)
Total Net Assets		100.00%	470,736,748

ALL SECURITIES ARE TRANSFERABLE SECURITIES ADMITTED TO AN OFFICIAL EXCHANGE LISTING OR TRADED ON A REGULATED MARKET EXCEPT FOR FORWARD FOREIGN CURRENCY CONTRACTS AND CONTRACTS-FOR-DIFFERENCE WHICH ARE FINANCIAL DERIVATIVE INSTRUMENTS

Analysis of Total Assets	% of Total Assets
Transferable securities admitted to an official exchange listing or traded on a regulated market	98.89%
Financial derivative instruments	0.74%
Other assets	0.37%
Total Assets	100.00%

The accompanying notes form an integral part of the financial statements

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS

1. Organisation and Structure

Sector Capital Funds plc (the “Company”) was incorporated and registered in Ireland with registered number 489443 and is governed by the Companies Acts 2014 as an open-ended umbrella investment company with variable capital and with segregated liability between sub-funds on 27 September 2010. The Company is authorised by the Central Bank of Ireland pursuant to European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019 (the “Regulations”).

The State of the origin of the Company is Ireland. In Switzerland, this document may only be provided to qualified investors within the meaning of art. 10 para. 3 and 3ter CISA. In Switzerland, the representative is Acolin Fund Services AG, Leutschenbachstrasse 50, 8050 Zurich, Switzerland, whilst the paying agent is Banque Hérédité SA, Route de Chêne 61, CH-1208 Geneva, Switzerland. The basic documents of the Company as well as the annual and, if applicable, semi-annual report may be obtained free of charge from the representative. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of shares.

As at 31 December 2023, the Company has two funds in existence (31 December 2022: one), Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund (the “Funds”).

Sector Emerging Markets Equities Fund commenced trading on 1 September 2023. The base currency of Sector Emerging Markets Equities Fund is United States Dollars (“USD”). As at 31 December 2023, three classes are subscribed to in the Fund, Class S GBP Shares, Class S NOK Shares and Class S USD Shares.

Sector Healthcare Value Fund commenced trading on 17 November 2010. The base currency of Sector Healthcare Value Fund is USD. As at 31 December 2023, fourteen classes are subscribed to in the Fund (31 December 2022: fourteen), Class A EUR Shares, Class A NOK Shares, Class A USD Shares, Class B EUR Shares, Class B NOK Shares, Class B SEK Shares, Class B USD Shares, Class X USD Shares, Class X EUR Shares, Class Y EUR Shares, Class Y GBP Shares, Class Y USD Shares, Class E NOK and Class E USD.

Investment Objective

The investment objective of Sector Emerging Markets Equities Fund is to invest primarily in equity and equity related securities (such as convertible bonds which may or may not embed derivatives and/or leverage, warrants, ordinary shares including depository receipts and preferred shares) listed or traded on a recognised exchange issued by companies trading, located in or deriving the majority of their revenue or profit from emerging market countries (including but not limited to Brazil, Chile, China, India, Indonesia, Korea, Mexico, Philippines, Taiwan and South Africa) (hereinafter referred to as “Equity Participations”). Investment in Equity Participations is subject to the maximum investment of 10% in any one equity security/issuer and/or as permitted by the investment restrictions below. The Equity Participations in which the Fund will invest will not have a sectoral focus. There can be no guarantee that the investment objective of the Fund will be achieved.

The investment objective of Sector Healthcare Value Fund is to achieve attractive long term investment returns relative to the MSCI Daily TR World Net Health Care USD (the “Index”). The Index is a capitalisation weighted index that monitors the performance of health care stocks from around the world. The Fund may invest in equities and financial instruments that are not part of the Index. There can be no guarantee that the investment objective of the Fund will be achieved.

2. Summary of Significant Accounting Policies

The financial statements have been prepared in accordance with Financial Reporting Standard 102 (“FRS 102”), the Financial Reporting Standard applicable in the UK and Republic of Ireland, the Companies Acts 2014, the Regulations.

The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss in accordance with the European Communities (Fair Value Accounting) Regulations 2011.

The Company has availed of certain exemptions available to open-ended investment funds in FRS 102 not to prepare a cash flow statement in paragraph 7.1A of FRS 102.

The preparation of financial statements in accordance with FRS 102 requires Directors to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the financial year. Actual results could differ from those estimates.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

The financial statements of the Company have been prepared on a going concern basis. The Company is able to meet all of its liabilities from its assets. The performance, marketability and risks of the Company are reviewed on a regular basis throughout the financial year. Therefore, the Directors believe that the Company will continue in operational existence for the foreseeable future and is financially sound. The Directors are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements of the Company.

(a) Portfolio valuation

Investment transactions

(i) Classification

The Company classifies all of its investments as financial assets or financial liabilities at fair value through profit or loss. These financial instruments are designated on the basis that their fair value can be reliably measured and their performance has been evaluated on a fair value basis in accordance with the risk management and/or investment strategy as set out in the Company's Prospectus.

(ii) Recognition

The Company recognises financial assets and financial liabilities on the date it becomes party to the contractual provisions of the instrument. Investment transactions are accounted for on a trade date basis at cost. Purchases and sales of securities are accounted for on the trade date on which the transaction takes place. Transaction costs are expensed immediately to the Profit and Loss Account and not capitalised as part of cost of the investment.

(iii) Measurement

Financial assets and financial liabilities held for trading are measured at fair value. Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction.

Realised gains and losses on sales of investments are calculated on a First-In, First-Out ("FIFO") basis. Unrealised gains and losses on investments are recognised in the Profit and Loss Account. Forward foreign currency contracts and any other instruments held by the Company and traded on an exchange will be measured at fair value based on the last reported traded price on such regulated market as at the relevant valuation point.

If an investment is quoted, listed or normally dealt in on more than one market, the Directors may, in their absolute discretion, select any of such markets for the valuation purposes.

(iv) Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition.

A financial liability is derecognised when the obligation specified in the contract is discharged, cancelled or expired.

(b) Forward foreign currency contracts

The unrealised gain or loss on open forward foreign currency contracts is calculated by reference to the difference between the contracted rate and the rate to close out the contract. Realised gains or losses include net gains on contracts which have been settled or offset by other contracts.

(c) Foreign exchange translation

Items included in the Company's financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). The functional currency of Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund is the United States Dollar ("USD"), due to the fact that the majority of the Fund's assets are denominated in USD and that a substantial portion of capital is issued in USD. Each Fund has adopted its functional currency as the presentation currency for these financial statements. Assets and liabilities expressed in foreign currencies are converted into the functional currency of each Fund using the exchange rates prevailing as at the balance sheet date. Transactions in foreign currencies are translated into the Fund's functional currency at exchange rates ruling at the transaction dates. Gains and losses on foreign exchange transactions are recognised in the Profit and Loss Account in determining the result for the year.

(d) Contracts-for-difference

A contract-for-difference ("CFD") is a contract between two parties, buyer and seller, stipulating that the seller will pay to the buyer the difference between the current value of an asset (a security, instrument, basket or index) and its value at contract time. The payment flows are usually netted against each other, with the differences being paid by one party to the other. The unrealised gain or loss depends upon the prices at which the underlying financial instruments of the CFD is valued at and is included in the Profit and Loss Account.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

2. Summary of Significant Accounting Policies (Continued)

(e) Offsetting financial instruments

Financial assets and financial liabilities may be offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. As at 31 December 2023 and 31 December 2022, no offsetting has been presented in the Balance Sheet.

(f) Income

Dividends are recognised as income on the dates that securities are first quoted “ex-dividend” to the extent information thereon is reasonably available to the Company. Interest income is accrued on a daily basis. Deposit interest is recognised as income on an accruals basis.

(g) Expenses

Operating expenses are accounted for on an accruals basis.

(h) Net asset value per share

The Net Asset Value per Share of each class is calculated by dividing the Net Asset Value attributable to a class by the number of shares of a class in issue as at the relevant valuation point.

(i) Redeemable participating shares

Shares issued by each Fund provide shareholders with the right to redeem their shares, for cash equal to their proportional share of the net asset value of the Fund and are classified as financial liabilities in accordance with FRS 102. The Funds do not meet the requirement to be classified as equity as the Fund offers different classes of shares with varying rights attached to them. The liabilities to shareholders are presented on the Balance Sheet as “Net assets attributable to holders of Redeemable Participating Shares” and are determined based on the residual assets of the Fund after deducting the Fund’s other liabilities.

(j) Amounts due from/to broker

Amounts due from/to broker relate to the outstanding amounts pending settlement on forward foreign currency contracts and upfront cash payments for fully funded contracts-for-difference.

(k) Taxation

The Company incurs dividend withholding tax and other taxation imposed by certain countries on investment income and gains on investments. Dividend income is shown gross of any non-recoverable withholding taxes, which are disclosed separately in Profit and Loss Account.

(l) Transaction costs

Transaction costs are costs incurred to acquire financial assets or financial liabilities at fair value through profit or loss. They include fees and commissions paid to agents, advisers, brokers and dealers. Transaction costs, when incurred, are immediately recognised in profit or loss as an expense. For the financial year ended 31 December 2023, Sector Emerging Markets Equities Fund incurred transaction costs of USD51,146 and Sector Healthcare Value Fund incurred transaction costs of USD185,753 (31 December 2022: USD336,158).

(m) Cash

Cash at bank and brokers represents, cash and cash equivalents, with original maturities of three months or less held with the Depositary and brokers.

3. Dividend and Distribution Policy

The Directors do not currently intend to pay dividends. Accordingly, the price of the shares shall rise as income and capital gains accrue.

4. Taxation

The Company will not be liable to tax in respect of its income and gains, other than on the occurrence of a chargeable event. Generally a chargeable event arises on any distribution, redemption, repurchase, cancellation, transfer of shares or on the ending of a ‘Relevant Year’, a ‘Relevant Year’ being an eight year period beginning with the acquisition of the shares by the shareholders and each subsequent year of eight years beginning immediately after the preceding relevant year.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

4. Taxation (Continued)

A chargeable event does not include:

- (i) Any transactions in relation to shares held in a recognised clearing system: or
- (ii) An exchange of shares representing a fund for another fund: or
- (iii) An exchange of shares arising on a qualifying amalgamation or reconstruction of a fund with another fund: or
- (iv) Certain exchanges of shares between spouses and former spouses.

A chargeable event will not occur in respect of shareholders who are neither resident nor ordinarily resident in Ireland and who have provided the Company with a relevant declaration to that effect.

In the absence of an appropriate declaration, the Company will be liable to Irish Tax on the occurrence of a chargeable event. There were no chargeable events during the year under review. Capital gains, dividends and interest received may be subject to withholding taxes imposed by the country of origin and such taxes may not be recoverable by the Company or its shareholders.

5. Exchange Rates

The following exchange rates (against USD) were used to convert the investments and other assets and liabilities denominated in currencies other than USD as at 31 December 2023 and 31 December 2022:

Currency	31 December 2023	31 December 2022
British Pound	0.7844	0.8313
Danish Krone	6.7484	6.9679
Euro	0.9053	0.9370
Hungarian Forint	346.0208	375.2345
Japanese Yen	140.9841	131.9435
Norwegian Krone	10.1557	9.8510
Swedish Krona	10.0778	10.4195
Swiss Franc	0.8417	0.9252

6. Cash

As at 31 December 2023 cash balances (including overdrafts) are held with The Bank of New York Mellon SA/NV, Dublin Branch (the "Depository") and Goldman Sachs. As at 31 December 2022 all cash balances (including overdrafts) are held with The Bank of New York Mellon SA/NV, Dublin Branch (the "Depository").

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
31 December 2023		
BNY Mellon	1,756,579	(1,266,539)
Goldman Sachs	767,405	-
	2,523,984	(1,266,539)
31 December 2022		
BNY Mellon		(1,283,950)
		(1,283,950)

Any overdrafts noted above are temporary in nature as they relate to timing differences only.

7. Financial Instruments and Associated Risks

Included in the Company's financial instruments, but not limited to, are global equities and equity related securities (including but not limited to American Depositary Receipts, Global Depositary Receipts, European Depositary Receipts and other equity based derivatives), corporate bonds and government debt obligations that shall be listed or traded on any market.

The main risks arising from the Company's financial instruments are market price, liquidity, interest rate, foreign currency and credit risks.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

The Market Risk Group (“MRG”) functions across all Sector Investment Manager entities and the group is responsible for defining risk management related limits (“soft limits”) in addition to the investment restrictions found in the Prospectus and related supplements, in cooperation with the respective Investment Manager, securing that the Funds have a portfolio construction and risk exposure that are in line with the intentions of the individual Funds. The limits are generally related to exposure towards single positions and sectors, total portfolio exposure and Value-at-Risk (“VAR”). MRG consists of the CEO of Sector Asset Management AS (leader of MRG), Head of Fund Operations, the CCO and CEO of Sector Fund Services AS. The Head of Fund Operations has the mandate to give short term exceptions to the risk limits set by MRG if he/she finds that under certain market conditions, the limits have unintended adverse effects, for example in extreme market conditions. Such exceptions are reported to the other members of MRG and to the Group Chief Compliance Officer.

(a) Market price risk

Market price risk arises from uncertainty concerning future prices of financial instruments. The consequence might be a decline in the Fund’s value. The risk related to the Funds – i.e. a combination of the probability of loss and the consequences – must be weighed against the potential gain for the Fund. To limit the risk, the Funds are both diversified and constructed through fundamental analyses of the expected behaviour and volatility of the individual instruments while following each Fund’s investment objective.

Value-at-Risk

Value-at-Risk (VaR) represents the potential loss one might suffer given a defined confidence interval and time horizon. The measure is one of the main risk measures for the Company under normal market conditions.

One of the key metrics used by the Sector Group to measure market risk is VAR which encompasses currency, interest rate and price risk.

The main risk management tool for VaR calculations was Bloomberg. For all Funds, the Bloomberg VaR calculation is based on Monte Carlo simulations at a 95% confidence interval i.e. that one in every 20 days is expected to be above this measure in the long run.

For the financial year ended 31 December 2023

	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Sector Emerging Markets Equities Fund	1.61%	91.7%	96.1%	0.07%	2.20%	1.70%
Sector Healthcare Value Fund	1.43%	97.3%	98.2%	1.27%	1.89%	1.54%

For the financial year ended 31 December 2022

	Period end VaR	Gross Exposure*	Net Exposure**	lowest VaR	highest VaR	average VaR
Sector Healthcare Value Fund	1.88%	96.7%	96.7%	1.51%	1.95%	1.75%

* Exposure as % of NAV

** Net open position as % of NAV

Exposure

Exposure for pure equities is equal to the fair value of the securities. The total gross exposure of each Fund is the sum of the absolute values of all long and short exposures.

(b) Interest rate risk

Interest rate risk is the risk (variability in value) borne by an interest-bearing asset, due to variability of interest rates. In general, as rates rise, the price of a fixed rate bond will fall, and vice versa. Interest rate risk is commonly measured by the bond's duration. For the financial year ended 31 December 2023 and 31 December 2022 the Funds have not invested in interest bearing assets, other than cash amounts. As at 31 December 2023 and 31 December 2022, the Funds do not have any significant fair value interest rate risk exposure.

Tables outlining the currency and interest exposure as at 31 December 2023 and 31 December 2022 are outlined in note 7(d).

(c) Liquidity risk

Liquidity risk is linked to the Funds having to realise assets in unfavourable market conditions with large losses as a consequence due to for example, redemptions in a Fund or a collapse in long asset values reducing the collateral held by counterparties leading to margin calls, if applicable. This means that there are two aspects that are monitored; what is the probability of the situation occurring and how fast can the Funds realise their positions without significant adverse effects on the value of the positions.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(c) Liquidity risk (continued)

Liquidity of portfolio

The Company's Prospectus provides for daily subscription and redemption of shares in the Funds, therefore the Funds are exposed to a liquidity risk of meeting shareholder redemptions on a daily basis. The majority of the Funds' assets are comprised of publicly traded securities and are thus relatively easily realised. Still, with each Fund having the possibility to take positions in small cap equities, the ability of a Fund to realise assets within a short period of time without a large negative impact on the value of the assets is important. Some of the recognised exchanges on which a Fund may invest may prove to be less liquid or highly volatile from time to time. The Funds may invest a limited proportion of their assets in unquoted securities.

For the financial year ended 31 December 2023 and 31 December 2022, the Funds held very liquid assets and liquidity was monitored daily by the Investment Manager.

The reports below are snapshots of the estimated liquidity of the Funds as at 31 December 2023 and 31 December 2022:

31 December 2023

Sector Emerging Markets Equities Fund

Description	Cumulative
< 1 day	97.0%
1-2 days	100.0%
3-5 days	100.0%
1-2 weeks	100.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

Sector Healthcare Value Fund

Description	Cumulative
< 1 day	91.0%
1-2 days	97.1%
3-5 days	99.0%
1-2 weeks	100.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

31 December 2022

Sector Healthcare Value Fund

Description	Cumulative
< 1 day	92.9%
1-2 days	98.4%
3-5 days	100%
1-2 weeks	100.0%
3-4 weeks	100.0%
> 4 weeks	100.0%

(d) Foreign currency risk

Foreign currency risk is in reality a sub-group of market risk, but with its own idiosyncrasies, both with respect to a Fund's portfolio as well as the investor classes denominated in different currencies. Certain currency related transactions may, for example, be employed by the Funds in order to hedge against foreign exchange risk subject to the conditions and limits laid down by the Central Bank of Ireland. Such transactions include forward foreign currency contracts and may for example be executed in cases where an investment is in a currency other than the Fund's functional currency.

A substantial portion of the financial assets of the Funds are denominated in currencies other than the relevant Fund's functional currency with the effect that the balance sheet of the Funds can be significantly affected by currency movements.

Currency exposure for investor classes

The shares of the Company are denominated in United States Dollar (USD), Euro (EUR), Norwegian Krone (NOK), British Pound (GBP), and Swedish Krona (SEK) and are issued and redeemed in those currencies. The Investment Manager may seek to hedge the foreign currency exposure of the assets attributable to the shares in order to neutralise as far as reasonably possible, the impact of fluctuations in exchange rates. This is done monthly in addition to when a Fund has more than 3% absolute return, month to date. There is no guarantee that such hedging will give returns that are equal regardless of which currency the shareholders have invested in. In addition, shareholders whose assets and liabilities are predominantly in currencies other than the currency of investment in the Company should take into account the potential risk of loss arising from fluctuations in value between USD, EUR, NOK, GBP or SEK being the currency of shareholder investment, and such other currencies as invested in by the Company.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (continued)

Portfolio currency exposure

The Funds trade in many different markets across the world and in many different currencies. Thus, certain assets in the portfolio may, regardless of the shares of the Fund, be invested in securities which are denominated in currencies other than USD, EUR, NOK, GBP or SEK. Consequently, the value of such assets will be affected either favourably or unfavourably by fluctuations in currency rates. The exposure towards the different currencies based on the denomination of the securities is reported daily for each Fund. For each individual Fund, action towards currency exposure in the portfolio is taken by the Investment Manager based on reported exposure of the Fund's assets.

Amounts represented below primarily are monetary assets and monetary liabilities except for investments in non-interest bearing securities, which include equities and contracts-for-difference, which are non-monetary assets.

The foreign currency exposure as at 31 December 2023 and 31 December 2022 are as follows:

31 December 2023

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Healthcare Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	8,721	—	—	38,679,972	—	—	38,688,693
DKK	107	—	—	8,980,862	—	—	8,980,969
EUR	42,674	131,646	—	41,220,107	—	—	41,394,427
GBP	75,802	—	—	42,074,462	—	382,914	42,533,178
JPY	13,832	—	—	37,010,430	—	115,672	37,139,934
NOK	76,238	3,367,444	—	—	—	—	3,443,682
SEK	13	18,295	—	3,882,791	—	—	3,901,099
USD	(1,483,926)	—	—	297,864,470	—	(1,725,778)	294,654,766
Total	(1,266,539)	3,517,385	—	469,713,094	—	(1,227,192)	470,736,748

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Emerging Markets Equities Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
AUD	1	—	—	301,430	—	—	301,431
CNY	—	—	—	497,225	(9,140)	—	488,085
EUR	3,980	—	—	565,533	—	—	569,513
GBP	7,285	—	—	—	—	—	7,285
HKD	—	—	—	562,870	—	(40,466)	522,404
IDR	—	—	—	1,632,637	—	—	1,632,637
INR	—	—	—	7,928,298	—	—	7,928,298
KRW	—	—	—	290,625	—	(38,547)	252,078
MXN	—	—	—	576,465	—	—	576,465
NOK	(454)	—	—	—	—	—	(454)
THB	—	—	—	232,308	—	(40,008)	192,300
TWD	—	—	—	1,178,638	—	5,869	1,184,507
USD	2,513,173	—	—	3,119,603	—	(33,997)	5,598,779
VND	—	—	—	33,632	—	—	33,632
ZAR	—	—	—	217,203	—	(39,023)	178,180
Total	2,523,984	—	—	17,136,467	(9,140)	(186,172)	19,465,139

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (continued)

Sector	Cash at Bank and Brokers	Forward Currency Contracts	Investments in Interest Bearing Assets	Investments in Non-Interest Bearing Assets	Investments in Non-Interest Bearing Liabilities	Net Other Assets/ (Liabilities)	Total Net Asset Value
Healthcare Value Fund							
Currency	USD	USD	USD	USD	USD	USD	USD
CHF	183	–	–	40,015,768	–	–	40,015,951
DKK	103	–	–	4,907,974	–	–	4,908,077
EUR	23,969	1,013,551	–	64,443,270	–	–	65,480,790
GBP	20,922	–	–	48,344,181	–	349,168	48,714,271
JPY	(90)	–	–	28,323,893	–	(270,776)	28,053,027
NOK	(1,365)	1,026,670	–	–	–	–	1,025,305
SEK	722	3,947	–	4,149,146	–	–	4,153,815
USD	(1,328,394)	–	–	345,343,107	–	(2,852,602)	341,162,111
Total	(1,283,950)	2,044,168	–	535,527,339	–	(2,774,210)	533,513,347

As at 31 December 2023 the following forward foreign currency contracts were held by Sector Healthcare Value Fund.

Sector Healthcare Value Fund

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2024	BNY Mellon	EUR	(1,092,833)	USD	1,215,318	7,935
02 January 2024	BNY Mellon	EUR	(381,151)	USD	423,870	2,767
02 January 2024	BNY Mellon	EUR	(23,819,986)	USD	26,489,730	172,954
02 January 2024	BNY Mellon	USD	(35,020)	EUR	32,195	550
02 January 2024	BNY Mellon	USD	(10,321)	EUR	9,488	161
02 January 2024	BNY Mellon	USD	(671,953)	EUR	617,740	10,538
02 January 2024	BNY Mellon	USD	(37,480)	EUR	34,242	351
02 January 2024	BNY Mellon	USD	(13,730)	EUR	12,544	129
02 January 2024	BNY Mellon	USD	(869,116)	EUR	794,039	8,153
02 January 2024	BNY Mellon	USD	(1,129,185)	EUR	1,026,396	4,797
02 January 2024	BNY Mellon	USD	(395,083)	EUR	359,119	1,679
02 January 2024	BNY Mellon	USD	(24,652,299)	EUR	22,408,207	104,717
01 February 2024	BNY Mellon	USD	(1,216,795)	EUR	1,092,833	(7,910)
01 February 2024	BNY Mellon	USD	(424,386)	EUR	381,151	(2,759)
01 February 2024	BNY Mellon	USD	(26,521,935)	EUR	23,819,986	(172,416)
02 January 2024	BNY Mellon	NOK	(219,250,443)	USD	21,709,448	118,325
02 January 2024	BNY Mellon	NOK	(356,655,439)	USD	35,314,832	192,478
02 January 2024	BNY Mellon	NOK	(164,815,997)	USD	16,319,530	88,947
02 January 2024	BNY Mellon	NOK	(2,106,616)	USD	206,309	(1,144)
02 January 2024	BNY Mellon	NOK	(1,316,093)	USD	128,206	(1,399)
02 January 2024	BNY Mellon	NOK	(1,068,404)	USD	104,078	(1,135)
02 January 2024	BNY Mellon	NOK	(296,886)	USD	28,892	(344)
02 January 2024	BNY Mellon	NOK	(188,995)	USD	18,346	(266)
02 January 2024	BNY Mellon	NOK	(2,280,174)	USD	219,190	(5,355)
02 January 2024	BNY Mellon	NOK	(2,607,211)	USD	249,269	(7,481)
02 January 2024	BNY Mellon	NOK	(722,367)	USD	69,064	(2,072)
02 January 2024	BNY Mellon	NOK	(44,688,212)	USD	4,265,892	(134,869)
02 January 2024	BNY Mellon	NOK	(61,146)	USD	5,837	(184)
02 January 2024	BNY Mellon	NOK	(749,798)	USD	70,043	(3,795)
02 January 2024	BNY Mellon	NOK	(2,740,405)	USD	254,266	(15,601)
02 January 2024	BNY Mellon	NOK	(2,017,136)	USD	187,158	(11,483)
02 January 2024	BNY Mellon	NOK	(6,052,490)	USD	557,464	(38,567)
02 January 2024	BNY Mellon	NOK	(651,310)	USD	59,989	(4,150)
02 January 2024	BNY Mellon	NOK	(1,995,857)	USD	183,594	(12,952)
02 January 2024	BNY Mellon	NOK	(734,565)	USD	67,364	(4,974)
02 January 2024	BNY Mellon	NOK	(3,800,484)	USD	346,311	(27,949)
02 January 2024	BNY Mellon	NOK	(137,663)	USD	12,540	(1,017)

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (continued)

Sector Healthcare Value Fund (continued)

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2024	BNY Mellon	NOK	(609,748)	USD	55,545	(4,501)
02 January 2024	BNY Mellon	USD	(19,456,332)	NOK	207,054,922	933,813
02 January 2024	BNY Mellon	USD	(37,704,024)	NOK	401,247,463	1,809,618
02 January 2024	BNY Mellon	USD	(15,033,214)	NOK	159,983,957	721,524
02 January 2024	BNY Mellon	USD	(7,260)	NOK	77,721	394
02 January 2024	BNY Mellon	USD	(511,910)	NOK	5,489,756	28,705
02 January 2024	BNY Mellon	USD	(990,946)	NOK	10,626,979	55,567
02 January 2024	BNY Mellon	USD	(394,812)	NOK	4,233,996	22,139
02 January 2024	BNY Mellon	USD	(91)	NOK	1,000	7
02 January 2024	BNY Mellon	USD	(22,859)	NOK	250,000	1,760
02 January 2024	BNY Mellon	USD	(38,475)	NOK	418,320	2,720
02 January 2024	BNY Mellon	USD	(70,269)	NOK	771,148	5,671
02 January 2024	BNY Mellon	USD	(32)	NOK	350	2
02 January 2024	BNY Mellon	USD	(641,758)	NOK	6,705,765	18,606
02 January 2024	BNY Mellon	USD	(1,266,072)	NOK	13,229,257	36,705
02 January 2024	BNY Mellon	USD	(518,710)	NOK	5,420,030	15,038
02 January 2024	BNY Mellon	USD	(48,967)	NOK	500,000	271
01 February 2024	BNY Mellon	NOK	(101,598)	USD	10,008	(5)
01 February 2024	BNY Mellon	USD	(21,727,003)	NOK	219,250,443	(119,097)
01 February 2024	BNY Mellon	USD	(35,343,389)	NOK	356,655,439	(193,736)
01 February 2024	BNY Mellon	USD	(16,332,727)	NOK	164,815,997	(89,528)
01 February 2024	BNY Mellon	USD	(19,596)	NOK	198,486	(34)
02 January 2024	BNY Mellon	SEK	(1,945)	USD	187	(6)
02 January 2024	BNY Mellon	SEK	(18,681)	USD	1,791	(63)
02 January 2024	BNY Mellon	SEK	(38,389)	USD	3,669	(141)
02 January 2024	BNY Mellon	SEK	(4,973)	USD	475	(18)
02 January 2024	BNY Mellon	SEK	(12,928)	USD	1,231	(52)
02 January 2024	BNY Mellon	SEK	(7,939,082)	USD	799,521	11,621
02 January 2024	BNY Mellon	USD	(732,808)	SEK	7,560,986	17,568
02 January 2024	BNY Mellon	USD	(19,002)	SEK	197,282	577
02 January 2024	BNY Mellon	USD	(25,155)	SEK	257,730	423
01 February 2024	BNY Mellon	SEK	(13,382)	USD	1,346	16
01 February 2024	BNY Mellon	USD	(800,523)	SEK	7,939,082	(11,630)
Total unrealised gain on forward foreign currency contracts						3,517,385

As at 31 December 2022 the following forward foreign currency contracts were held by Sector Healthcare Value Fund:

Sector Healthcare Value Fund

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
02 January 2023	BNY Mellon	USD	(6,084,961)	EUR	5,701,266	13,842
02 January 2023	BNY Mellon	USD	(416,141)	EUR	389,901	947
02 January 2023	BNY Mellon	USD	(35,625,852)	EUR	33,379,417	81,040
03 January 2023	BNY Mellon	EUR	(176,934)	USD	188,310	(577)
03 January 2023	BNY Mellon	EUR	(11,863)	USD	12,626	(38)
03 January 2023	BNY Mellon	EUR	(1,007,844)	USD	1,072,644	(3,284)
03 January 2023	BNY Mellon	EUR	(5,701,266)	USD	6,072,418	(13,989)
03 January 2023	BNY Mellon	EUR	(389,901)	USD	415,284	(956)
03 January 2023	BNY Mellon	EUR	(33,379,417)	USD	35,552,417	(81,901)
03 January 2023	BNY Mellon	USD	(5,952,678)	EUR	5,713,801	147,111
03 January 2023	BNY Mellon	USD	(406,892)	EUR	390,564	10,056
03 January 2023	BNY Mellon	USD	(34,795,360)	EUR	33,399,046	859,913

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(d) Foreign currency risk (continued)

Sector Healthcare Value Fund (continued)

Maturity Date	Counterparty	Sale Currency	Amount	Purchase Currency	Amount	Unrealised gain/(loss) USD
03 January 2023	BNY Mellon	USD	(175,309)	EUR	164,399	196
03 January 2023	BNY Mellon	USD	(11,943)	EUR	11,200	14
03 January 2023	BNY Mellon	USD	(1,053,794)	EUR	988,215	1,178
02 January 2023	BNY Mellon	USD	(24,949,761)	NOK	246,640,865	122,138
02 January 2023	BNY Mellon	USD	(72,035,699)	NOK	712,108,900	352,639
02 January 2023	BNY Mellon	USD	(21,290)	NOK	210,237	81
02 January 2023	BNY Mellon	USD	(4,291)	NOK	42,376	17
02 January 2023	BNY Mellon	USD	(13,556,038)	NOK	134,008,209	66,361
02 January 2023	BNY Mellon	USD	(14,282)	NOK	140,594	10
03 January 2023	BNY Mellon	NOK	(637,202)	USD	65,442	747
03 January 2023	BNY Mellon	NOK	(2,038,903)	USD	209,097	2,087
03 January 2023	BNY Mellon	NOK	(133,938)	USD	13,626	27
03 January 2023	BNY Mellon	NOK	(248,464)	USD	25,181	(46)
03 January 2023	BNY Mellon	NOK	(7,547,195)	USD	764,036	(2,230)
03 January 2023	BNY Mellon	NOK	(21,438,266)	USD	2,170,291	(6,335)
03 January 2023	BNY Mellon	NOK	(4,159,134)	USD	421,048	(1,229)
03 January 2023	BNY Mellon	NOK	(246,640,865)	USD	24,918,253	(123,180)
03 January 2023	BNY Mellon	NOK	(712,108,900)	USD	71,944,726	(355,650)
03 January 2023	BNY Mellon	NOK	(134,008,209)	USD	13,538,918	(66,928)
03 January 2023	BNY Mellon	NOK	(92,239)	USD	9,285	(80)
03 January 2023	BNY Mellon	NOK	(28,931,821)	USD	2,903,190	(34,256)
03 January 2023	BNY Mellon	NOK	(5,647,898)	USD	566,761	(6,670)
03 January 2023	BNY Mellon	NOK	(214,485)	USD	21,515	(262)
03 January 2023	BNY Mellon	NOK	(76,405)	USD	7,656	(101)
03 January 2023	BNY Mellon	USD	(24,822,593)	NOK	246,889,726	244,107
03 January 2023	BNY Mellon	USD	(74,268,379)	NOK	738,685,928	730,361
03 January 2023	BNY Mellon	USD	(10,572,975)	NOK	105,160,607	103,975
03 January 2023	BNY Mellon	USD	(555,495)	NOK	5,533,318	6,302
03 January 2023	BNY Mellon	USD	(2,872,954)	NOK	28,630,501	33,899
03 January 2023	BNY Mellon	USD	(4,067)	NOK	39,604	(46)
03 January 2023	BNY Mellon	USD	(61,334)	NOK	605,073	99
03 January 2023	BNY Mellon	USD	(8,782)	NOK	86,634	14
03 January 2023	BNY Mellon	USD	(11,867)	NOK	118,592	174
03 January 2023	BNY Mellon	USD	(743,044)	NOK	7,228,334	(9,152)
03 January 2023	BNY Mellon	USD	(2,190,868)	NOK	21,312,761	(26,985)
03 January 2023	BNY Mellon	USD	(426,603)	NOK	4,149,998	(5,254)
03 January 2023	BNY Mellon	USD	(10,840)	NOK	107,376	62
03 January 2023	BNY Mellon	USD	(6,478)	NOK	64,356	56
03 January 2023	BNY Mellon	USD	(7,082)	NOK	70,000	25
03 January 2023	BNY Mellon	USD	(437,628)	NOK	4,325,896	1,580
03 January 2023	BNY Mellon	USD	(3,311)	NOK	32,673	6
03 January 2023	BNY Mellon	USD	(88,999)	NOK	879,577	304
03 January 2023	BNY Mellon	USD	(301)	NOK	2,970	1
02 January 2023	BNY Mellon	USD	(916,599)	SEK	9,582,488	4,871
03 January 2023	BNY Mellon	SEK	(12,139)	USD	1,175	10
03 January 2023	BNY Mellon	SEK	(5,075)	USD	491	4
03 January 2023	BNY Mellon	SEK	(40,826)	USD	3,950	31
03 January 2023	BNY Mellon	SEK	(293,090)	USD	28,262	126
03 January 2023	BNY Mellon	SEK	(126,831)	USD	12,220	45
03 January 2023	BNY Mellon	SEK	(57,096)	USD	5,486	5
03 January 2023	BNY Mellon	SEK	(9,582,488)	USD	914,979	(4,912)
03 January 2023	BNY Mellon	USD	(941,310)	SEK	9,850,955	4,353
03 January 2023	BNY Mellon	USD	(26,177)	SEK	266,590	(585)
Total unrealised gain on forward foreign currency contracts						2,044,168

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(e) Credit risk

Credit risk is the risk that a counterparty will fail to discharge an obligation or commitment that it has entered into with the Funds, resulting in a financial loss to the Funds.

The Funds are exposed to credit risk associated with counterparties with whom it trades or holds assets, and will also be exposed to the risk of settlement default. All transactions in listed securities are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has made payment. Payment is made on a purchase once the securities have been delivered by the broker. The trade will fail if either party fails to meet its obligation.

Management of credit risk

The Investment Manager is complying with the Central Bank UCITS Regulations in terms of investment restrictions and otherwise with the investment policy of the Sub-Funds.

Exposure to credit risk

The sub-fund's maximum credit risk exposure at the Balance Sheet date is represented by the respective carrying amounts of the financial assets in the Balance Sheet with the exception of derivatives whose maximum credit risk exposure is notional exposure.

Derivative financial instruments

The Funds may also invest in financial derivative instruments for investment purposes and for efficient portfolio management ("EPM"), including (but not limited to) futures, forwards, options, contracts for difference and warrants.

All cleared derivative positions entered into on behalf of the Funds are cleared via Goldman Sachs as appointed Futures Commission Merchant ("FCMs"). Bilateral (non-cleared) derivatives face BNY as OTC credit counterparty.

Trade counterparty

The Funds mitigate counterparty risk by undertaking transactions with large and well capitalised counterparties. The Funds also seek to trade with more than one counterparty and have reduced the activity with counterparties when there have been questions raised regarding the robustness of counterparties in terms of credit risk.

Although it is the intention of the Investment Manager to follow a general policy of seeking to spread the Funds' capital at risk over a number of investments and counterparties, the Funds may at certain times hold relatively few positions with the result that a loss in any such position either to trading counterparty or settlement default could have a substantial adverse impact on a Fund's capital. The relevant Standard and Poor's ratings are as follows:

	31 December 2023	31 December 2022
The Bank of New York Mellon SA/NV	A	A
Goldman Sachs	BBB+	n/a

(f) Fair value estimation

The Company used the following fair value hierarchy levels in categorising its financial instruments by source of inputs used to determine its fair value:

Level 1: The unadjusted quoted price in an active market for identical assets or liabilities that the entity can access at the measurement date.

Level 2: Inputs other than quoted prices included within Level 1 that are observable (i.e. developed using market data) for the asset or liability, either directly or indirectly.

Level 3: Inputs are unobservable (i.e. for which market data is unavailable) for the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Company. The Company considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

Investments classified as Level 3 are those for which a quoted price at year end was unavailable and evidence of a recent transaction at that date could not be ascertained. These investments represent collective investment schemes where the net asset value is calculated by an underlying administrator. The net asset values represent their best evidence of the fair value of these assets at year end, however due to the lack of quoted price and evidence of a recent transaction, a Level 3 classification is considered appropriate.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(f) Fair value estimation (continued)

The level in the fair value hierarchy within which the fair value measurement is categorised is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses inputs that are unobservable, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

There were no significant transfers between levels during the financial year ended 31 December 2023 or 31 December 2022. Transfers between levels of the fair value hierarchy, for the purpose of disclosure in financial statements, are deemed to have occurred at the end of the reporting period.

The fair values of investments valued under Levels 1 to 3 for Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund and at 31 December 2023 are as follows.

31 December 2023

Sector Emerging Markets Equities Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	17,102,835	–	–	17,102,835
Derivative instruments	–	33,632	–	33,632
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(9,140)	–	(9,140)
Total	17,102,835	24,492	–	17,127,327

31 December 2023

Sector Healthcare Value Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	457,495,908	–	–	457,495,908
Derivative instruments	–	4,397,226	–	4,397,226
Money market instrument	12,217,186	–	–	12,217,186
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(879,841)	–	(879,841)
Total	469,713,094	3,517,385	–	473,230,479

The categories of investments above comprise:

- Equity securities (which includes equities and money market funds).
- Derivative instruments (forward foreign currency contracts and contracts for difference).

The fair values of investments valued under Levels 1 to 3 for Sector Healthcare Value Fund as at 31 December 2022 are as follows:

Sector Healthcare Value Fund	Level 1 USD	Level 2 USD	Level 3 USD	Total USD
Financial assets at fair value through profit or loss				
Equity securities	516,261,566	–	–	516,261,566
Derivative instruments	–	2,788,814	–	2,788,814
Money market instrument	19,265,773	–	–	19,265,773
Financial liabilities at fair value through profit or loss				
Derivative instruments	–	(744,646)	–	(744,646)
Total	535,527,339	2,044,168	–	537,571,507

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

7. Financial Instruments and Associated Risks (Continued)

(f) Fair value estimation (continued)

The categories of investments above comprise:

- Equity securities (which includes equities and money market funds).
- Derivative instruments (forward foreign currency contracts).

8. Share Capital

The authorised share capital of the Company is 1,000,000,000,000 Shares of no par value initially designated as unclassified shares. The issued share capital of the Company is €2 represented by 2 shares (the “Subscriber Shares”) issued for the purposes of the incorporation of the Company at an issue price of €1 per Share which are fully paid up and which are beneficially owned by Sector Asset Management AS and Prieren AS.

Sector Emerging Markets Equities Fund may issue Class S USD Shares, Class S GBP Shares, Class S EUR Shares, Class S CHF Shares, Class S NOK Shares and Class S SEK Shares (the “Class S Shares”), Class I USD Shares, Class I GBP Shares, Class I EUR Shares, Class I CHF Shares, Class I NOK Shares and Class I SEK Shares (the “Class I Shares”), Class LI USD Shares, Class LI GBP Shares, Class LI EUR Shares, Class LI CHF Shares, Class LI NOK Shares and Class LI SEK Shares (the “Class LI Shares”), Class P USD Shares, Class P GBP Shares, Class P EUR Shares, Class P CHF Shares, Class P NOK Shares and Class P SEK Shares (the “Class P Shares”), and Class R USD Shares, Class R GBP Shares, Class R EUR Shares, Class R CHF Shares, Class R NOK Shares and Class R SEK Shares (the “Class R Shares”).

Sector Healthcare Value Fund may issue Class A EUR Shares, Class A USD Shares, Class A NOK Shares and Class A SEK Shares, (the “Class A Shares”), Class B EUR Shares, Class B USD Shares, Class B NOK Shares and Class B SEK (the “Class B Shares”), Class E EUR Shares, Class E SEK Shares, Class E NOK Shares and Class E USD Shares (the “Class E Shares”), Class X EUR Shares and Class X USD Shares (the “Class X Shares”) and Class Y EUR Shares, Class Y GBP Shares and Class Y USD Shares (the “Class Y Shares”).

On a show of hands every holder who is present in person or by proxy shall have one vote and the holders of Subscriber Shares present or in person or by proxy shall have one vote.

The rights attached to any class may be varied or abrogated with the consent in writing of the holders of three-fourths in number of the issued Shares of that class, or with the sanction of a special resolution passed at a separate general meeting of the holders of the Shares of the class, and may be so varied or abrogated either whilst the Company is a going concern or during or in contemplation of a winding-up. The quorum at any such separate general meeting, other than an adjourned meeting, shall be two persons holding or representing by proxy at least one third of the issued Shares of the class in question and the quorum at an adjourned meeting shall be one person holding Shares of the class in question or his proxy.

The following are the share class transactions for the financial year ended 31 December 2023 were as follows:

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class A EUR		
Shares in issue at beginning of year	–	17,009
Number of shares issued	–	282
Number of shares redeemed	–	(14,015)
Number in issue at end of year	–	<u>3,276</u>
Class A NOK		
Shares in issue at beginning of year	–	81,322
Number of shares issued	–	26
Number of shares redeemed	–	(9,081)
Number in issue at end of year	–	<u>72,267</u>
Class A USD		
Shares in issue at beginning of year	–	32,892
Number of shares issued	–	4,237
Number of shares redeemed	–	(14,320)
Number in issue at end of year	–	<u>22,809</u>

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class B EUR		
Shares in issue at beginning of year	–	2,840
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	–	2,840
Class B NOK		
Shares in issue at beginning of year	–	444,096
Number of shares issued	–	88,148
Number of shares redeemed	–	(305,063)
Number in issue at end of year	–	227,181
Class B SEK		
Shares in issue at beginning of year	–	6,361
Number of shares issued	–	–
Number of shares redeemed	–	(968)
Number in issue at end of year	–	5,393
Class B USD		
Shares in issue at beginning of year	–	437,005
Number of shares issued	–	173,150
Number of shares redeemed	–	(211,291)
Number in issue at end of year	–	398,864
Class X EUR		
Shares in issue at beginning of year	–	309,159
Number of shares issued	–	–
Number of shares redeemed	–	(86,767)
Number in issue at end of year	–	222,392
Class X USD		
Shares in issue at beginning of year	–	235,820
Number of shares issued	–	10,085
Number of shares redeemed	–	(72,707)
Number in issue at end of year	–	173,198
Class E NOK		
Shares in issue at beginning of year	–	1,298,204
Number of shares issued	–	1,818,765
Number of shares redeemed	–	(1,500,006)
Number in issue at end of year	–	1,616,963
Class E USD		
Shares in issue at beginning of year	–	116,749
Number of shares issued	–	120,549
Number of shares redeemed	–	(46,067)
Number in issue at end of year	–	191,231
Class S GBP		
Shares in issue at beginning of year	–	–
Number of shares issued	56,884	–
Number of shares redeemed	(2,132)	–
Number in issue at end of year	54,752	–

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class S NOK		
Shares in issue at beginning of year	–	–
Number of shares issued	1,024,623	–
Number of shares redeemed	(38,634)	–
Number in issue at end of year	985,989	–
Class S USD		
Shares in issue at beginning of year	–	–
Number of shares issued	77,392	–
Number of shares redeemed	(45,000)	–
Number in issue at end of year	32,392	–
Class Y EUR		
Shares in issue at beginning of year	–	33,220
Number of shares issued	–	4,169
Number of shares redeemed	–	(13,766)
Number in issue at end of year	–	23,623
Class Y GBP		
Shares in issue at beginning of year	–	988,051
Number of shares issued	–	82,744
Number of shares redeemed	–	(93,054)
Number in issue at end of year	–	987,741
Class Y USD		
Shares in issue at beginning of year	–	563,795
Number of shares issued	–	82,876
Number of shares redeemed	–	(61,369)
Number in issue at end of year	–	585,302

The following are the share class transactions for the financial year ended 31 December 2022 were as follows:

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class A EUR		
Shares in issue at beginning of year	–	19,729
Number of shares issued	–	7,499
Number of shares redeemed	–	(10,219)
Number in issue at end of year	–	17,009
Class A NOK		
Shares in issue at beginning of year	–	78,290
Number of shares issued	–	3,256
Number of shares redeemed	–	(224)
Number in issue at end of year	–	81,322
Class A USD		
Shares in issue at beginning of year	–	55,831
Number of shares issued	–	9,563
Number of shares redeemed	–	(32,502)
Number in issue at end of year	–	32,892

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class B EUR		
Shares in issue at beginning of year	–	2,840
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	–	2,840
Class B NOK		
Shares in issue at beginning of year	–	485,271
Number of shares issued	–	68,810
Number of shares redeemed	–	(109,985)
Number in issue at end of year	–	444,096
Class B SEK		
Shares in issue at beginning of year	–	16,855
Number of shares issued	–	493
Number of shares redeemed	–	(10,987)
Number in issue at end of year	–	6,361
Class B USD		
Shares in issue at beginning of year	–	283,700
Number of shares issued	–	300,020
Number of shares redeemed	–	(146,715)
Number in issue at end of year	–	437,005
Class X EUR		
Shares in issue at beginning of year	–	309,159
Number of shares issued	–	–
Number of shares redeemed	–	–
Number in issue at end of year	–	309,159
Class X USD		
Shares in issue at beginning of year	–	268,132
Number of shares issued	–	24,954
Number of shares redeemed	–	(57,266)
Number in issue at end of year	–	235,820
Class E NOK		
Shares in issue at beginning of year	–	306,725
Number of shares issued	–	1,014,403
Number of shares redeemed	–	(22,924)
Number in issue at end of year	–	1,298,204
Class E USD		
Shares in issue at beginning of year	–	73,494
Number of shares issued	–	50,434
Number of shares redeemed	–	(7,179)
Number in issue at end of year	–	116,749
Class Y EUR		
Shares in issue at beginning of year	–	38,054
Number of shares issued	–	1,284
Number of shares redeemed	–	(6,118)
Number in issue at end of year	–	33,220

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

8. Share Capital (Continued)

	Sector Emerging Markets Equities Fund	Sector Healthcare Value Fund
Class Y GBP		
Shares in issue at beginning of year	–	657,122
Number of shares issued	–	366,391
Number of shares redeemed	–	(25,462)
Number in issue at end of year	–	998,051
Class Y USD		
Shares in issue at beginning of year	–	506,802
Number of shares issued	–	123,618
Number of shares redeemed	–	(66,625)
Number in issue at end of year	–	563,795

9. Investment Management Fees

The Company has appointed Sector Fund Services AS as the Investment Manager.

Sector Emerging Markets Equities Fund and Sector Healthcare Value Fund pays the Investment Manager a management fee per annum of the Net Asset Value of each of the following classes:

Sector Emerging Markets Equities Fund		Sector Healthcare Value Fund	
Class	Management Fee	Class	Management Fee
Class P Shares	Up to 0.30%	Class A Shares	Up to 1.0%
Class S Shares	Up to 0.55%	Class B Shares	Up to 2.0%
Class LI Shares	Up to 0.65%	Class E Shares	Up to 1.0%
Class I Shares	Up to 0.75%	Class X Shares	Up to 0.50%
Class R Shares	Up to 1.25%	Class Y Shares	Up to 0.40%

The Investment Manager to Sector Emerging Markets Equities Fund does not anticipate that the "Total Expense Ratio" which includes but is not limited to the management fee, administration fees and expenses, depositary fees and expenses, establishment costs of the Fund and other operating expenses of the Fund (excluding trading costs) will exceed 1.5% of the Net Asset Value of the Fund (the "TER Threshold"). If the Total Expense Ratio exceeds the TER Threshold, the Investment Manager has undertaken to discharge that proportion of the Total Expense Ratio above the TER Threshold and shall rebate the Fund accordingly.

The total management fees accrued for the financial year ended 31 December 2023 were USD4,625,503 (31 December 2022: USD4,689,054) and the net amount outstanding at 31 December 2023 was USD378,079 (31 December 2022: USD453,956).

10. Incentive Fees/Performance Fees

The Investment Manager is also entitled to receive an incentive fee/performance fee ("Incentive Fee" / "Performance Fee"), as calculated for each Fund as disclosed below. The Incentive Fee/Performance Fee will be verified by the Depositary.

Sector Emerging Markets Equities Fund

The Fund, in respect of the Class P Shares paid the Investment Manager an incentive fee (the "Incentive Fee") equal to 20% of the amount by which the Net Asset Value (before the deduction of any performance fee) of the relevant Class exceeds the MSCI ACWI Index ("Index") adjusted Prior High Net Asset Value ("Index adjusted Prior High Net Asset Value") (as defined below). The Incentive Fee shall only be payable on the amount by which each Share outperforms the Index adjusted Prior High Net Asset Value for the relevant Share. No incentive fee will be charged in respect of the S Shares, LI Shares I Shares and R Shares.

The Incentive Fee is calculated and accrued at each Valuation Point in respect of each calendar year, in each case concluding and crystallising on the last Business Day of the relevant calendar year or, in the case of redemptions, as of each Dealing Day in due proportions to the Shares redeemed by redeeming Shareholders. The Incentive Fee (if any) will become payable to the Investment Manager within 10 Business Days of crystallisation.

The first Incentive Fee Period for any new or unlaunched Shares (that pays an Incentive Fee) shall commence from the conclusion of the relevant Initial Offer Period and cease on the last Business Day of the relevant calendar year (save in circumstances whereby a period of less than 12 months has elapsed since the creation of such new or unlaunched Shares, in which case the calculation period shall end on the last Business Day of the following calendar year).

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

10. Incentive Fees/Performance Fees (Continued)

At the end of each calculation period, where an Incentive Fee has been paid, and only then, the Prior High Net Asset Value per Share will be reset to the Net Asset Value per Share of the Class at the end of such calculation period. For the avoidance of doubt, where the Class has underperformed, (i.e. its Net Asset Value per Share at the end of a calculation period is below the Index adjusted Prior High Net Asset Value per Share), no Incentive Fee will be payable until the underperformance is clawed back.

Sector Healthcare Value Fund

The Fund, in respect of the Class A Shares, pays the Investment Manager a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the MSCI Daily TR World Net Healthcare USD (the “Index”). In respect of Class E Shares, a fee equal to 20% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index adjusted Prior High Net Asset Value (the “Incentive Fee”). In respect of Class X Shares and Class Y Shares, a fee equal to 15% of the amount by which the net asset value (before the deduction of any performance fee) of the relevant share exceeds the Index Net Asset Value (the “Incentive Fee”).

The relevant share's subscription price or the initial issue price (where shares are issued during the initial offer year) is taken as the starting price for the purposes of determining the Incentive Fee. The Incentive Fee is accrued on a daily basis and reflected in the net asset value per share at each valuation point. The accrued Incentive Fee will only be paid to the Investment Manager once a shareholder redeems its investment in the Fund or when the Fund closes down where the performance of the relevant shares has exceeded the performance of the Index. The Incentive Fee may be payable even if the absolute return on the shareholder's investment is zero or negative. For example, if during the year of a shareholder's investment in the Fund, the net asset value per share on redemption is less than or equal to the net asset value per share that that shareholder paid on its initial subscription into the Fund, the Incentive Fee may still be payable if the net asset value per share on redemption exceeds the Index Net Asset Value per share, i.e. the Fund has outperformed the Index for the year of the shareholder's investment. No Incentive Fee will be charged in respect of the Class B Shares.

During the year ended 31 December 2023, there was a reversal of accrued performance fees which resulted in a net credit of USD9,471 to the profit and loss account with USD 158,518 payable at year end. The total performance fees accrued for the financial year ended 31 December 2022 were USD51,233 and the net amount outstanding was USD243,401.

Equalisation Credit

The equalisation credit policy is applied to the calculation of the Incentive Fee payable for certain classes in each Fund (see the Fund's relevant Supplement for further details). The Incentive Fee is calculated on a share-by-share basis so that each relevant share is charged an Incentive Fee that equates precisely with that relevant share's performance. This method of calculation ensures that (i) the Incentive Fee is charged only to those relevant shares that have appreciated in value relative to the Index, (ii) all relevant shareholders have the same amount per relevant share of the relevant class at risk in the Fund, and (iii) all shares of the same class have the same net asset value per share. If a shareholder subscribes for relevant shares at a time when the net asset value per relevant share is other than the Index Net Asset Value, certain adjustments will be made to reduce inequities that could otherwise result to the subscriber or beneficiary of the Incentive Fee. For the financial year ended 31 December 2023 an equalisation of USD(62,451) (31 December 2022: equalisation of USD592,218) was applied by the Company.

11. Administration Fees and Depositary/Custodian Fees

The Company has appointed BNY Mellon Fund Services (Ireland) Designated Activity Company (“BNY Mellon”) to act as Administrator, registrar and transfer agent and The Bank of New York Mellon SA/NV, Dublin Branch to act as Depositary (the “Depositary”). BNY Mellon is entitled to a shareholding services fee of USD1,875 per share class per month together with agreed upon transaction charges. The Administrator is also entitled to a financial reporting fee of up to USD7,000 per set of annual financial statements and a financial reporting fee of USD2,000 per set of interim financial statements and other out of pocket expenses out of the assets of the Fund (plus VAT). BNY Mellon is entitled to receive out of the assets of the Fund an annual administration fee, accrued and calculated on each dealing day and payable monthly in arrears and is illustrated in more detail in the table below.

- i. 0.07% of the first USD 250 million of aggregated average Net Asset Value;
- ii. 0.057% of the next USD 250 million of aggregated average Net Asset Value in excess of USD 250 million;
- iii. 0.042% of the next USD 250 million of aggregated average Net Asset Value in excess of USD 500 million;
- iv. 0.03% of the next USD 250 million of aggregated average Net Asset Value in excess of USD 750 million;
- v. 0.02% of the aggregated average Net Asset Value in excess of USD 1 billion;

subject to a minimum annual fee of USD 40,000 (plus VAT).

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

11. Administration Fees and Depositary/Custodian Fees (Continued)

The Administration fee accrued for the financial year ended 31 December 2023 was USD566,391 (31 December 2022: USD550,183) and the amount outstanding at 31 December 2023 was USD222,982 (31 December 2022: USD425,459).

The Depositary is entitled to an asset based fee per annum payable monthly together with sub-custodians' fees (which will be charged at normal commercial rates) as well as agreed upon transaction charges (which will be at normal commercial rates) and other out of pocket expenses (plus VAT) and as illustrated in the table overleaf.

- 0.02% of the first USD 200 million of aggravated average Net Asset Value; and
- 0.015% of the aggregated average Net Asset Value in excess of USD 200 million;

subject to a minimum annual fee of USD 30,000 (plus VAT).

The Depositary fee accrued for the financial year ended 31 December 2023 was USD218,524 (31 December 2022: USD179,091) and the amount outstanding at 31 December 2023 was USD36,910 (31 December 2022: USD57,346).

12. Directors' Fees and Expenses

The Directors shall be entitled to a fee in remuneration for their services at a rate to be determined from time to time by the Directors, but so that the aggregate amount of each Director's remuneration in any one year shall not exceed EUR25,000 (31 December 2022: EUR25,000) or such higher amount as may be approved by resolution of the Directors and notified to shareholders. The Directors may also be paid all travelling, hotel and other expenses, properly incurred by them, in attending and returning from meetings of the Directors or general meetings of the Company or in connection with the business of the Company. The Directors may in addition to such remuneration as aforesaid grant special remuneration to any Director who, being called upon, shall perform any special or extra services to or at the request of the Company and such remuneration will be at normal commercial rates. The Directors' fees and expenses accrued for the financial year ended 31 December 2023 was USD39,681 (31 December 2022: USD35,313) and the amount outstanding at 31 December 2023 was USD9,612 (31 December 2022: USD9,233).

13. Auditors' Fees

Fees and expenses paid to the statutory auditors, Deloitte Ireland LLP, in respect of the financial year, entirely relate to the audit of the financial statements of the Company.

Audit fees charged for the financial year ended 31 December 2023 were EUR18,000 ex VAT (31 December 2022: EUR13,250). Tax compliance fees charged for the financial year ended 31 December 2023 were EUR8,600 ex VAT (31 December 2022: EUR8,600).

14. Efficient Portfolio Management

The Company may enter into a variety of derivative instruments including, but not limited to, forward foreign exchange contracts, futures, options, swaps, contracts-for-difference, stock lending and repurchase agreements for the purposes of efficient portfolio management only, subject to the conditions and limits set out in the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the "Central Bank UCITS Regulations") and within any further limits laid down by the Central Bank of Ireland from time to time. In particular, the Funds may engage in forward foreign exchange contracts to provide protection against exchange rate risks, including cross-currency hedging, and in order to hedge foreign currency exposure of the underlying assets of the Funds into the base currency of the Funds or into a currency institutionally linked to the base currency. It is intended that the use of such forwards may reduce the currency risk in respect of the Funds and will better enable the Funds to manage its assets and liabilities. Futures contracts may be used to hedge or gain exposure to an increase in the value of an asset, market, currency, or deposit. Options may be used to hedge or achieve exposure to a particular market instead of using a physical security. Swaps may be used to achieve profit as well as to hedge existing long positions. Contracts-for-difference ("CFDs") are bilateral agreements to exchange the difference between opening and closing contracts, which represent the performance of an underlying share.

At the discretion of the Directors, the Funds may use financial derivative instruments as a primary investment policy and details of the investment policy will be set out in the applicable Supplement in accordance with the requirements of the Central Bank of Ireland.

For the year ended 31 December 2023 and 31 December 2022, the Company has utilised forward foreign currency contracts. As at 31 December 2023, all derivatives are OTC derivatives. All open derivative positions are disclosed in the schedule of investments except for forward currency contracts which are disclosed in note 7 (d) above.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

15. Directors' Interests, Connected Persons and Related Party Transactions

Fees payable to the relevant Investment Manager are disclosed in notes 9 and 10.

Depository and Administrator

Although not deemed to be related parties under FRS 102 as they do not exercise "significant influence" over the activities of the Company, the Regulations also deem a "Depository" and its "associated or group companies" to be "connected persons" to the Company. As such, The Bank of New York Mellon SA/NV, Dublin Branch, the Depository, and BNY Mellon Fund Services (Ireland) Designated Activity Company, the Administrator, are connected persons to the Company.

The Board of Directors is satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that any transaction carried out with the Company by a promoter, manager, depository/custodian, investment manager and/or associated or group companies of these ("connected persons") are carried out as if negotiated at arm's length and that all such transactions are carried out in the best interests of the shareholders. The Board of Directors are satisfied that transactions with connected persons entered into during the year complied with the obligations set out in the Regulations.

31 December 2023

Key personnel	Role/Team	Fund/Class	Number of Shares held
Tellaviva AS/Lars Tell	Director/Manager	Sector Healthcare Value Fund, Class A NOK	374
ETHO AS/ Trond Horneland	Investment Manager	Sector Healthcare Value Fund, Class A NOK	22,040
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, Class B SEK	118

31 December 2022

Key personnel	Role/Team	Fund/Class	Number of Shares held
Tellaviva AS/Lars Tell	Director/Manager	Sector Healthcare Value Fund, Class A NOK	348
ETHO AS/ Trond Horneland	Investment Manager	Sector Healthcare Value Fund, Class A NOK	22,040
Sector Gamma AS	Investment Manager	Sector Healthcare Value Fund, Class B SEK	118

As at 31 December 2023 and 31 December 2022, Sector Asset Management AS held 3 Class A EUR Shares, 2 Class A NOK Shares and 3 Class A USD Shares in Sector Healthcare Value Fund and 200 Class S USD Shares in Sector Emerging Markets Equities Fund.

16. Contingent Liabilities

The Company is established as a segregated portfolio company. As a matter of Irish law, the assets of one Fund will not be available to satisfy the liabilities of another. However, the Company is a single legal entity which may operate or have assets held on its behalf or be subject to claims in other jurisdictions which may not necessarily recognise such segregation. There is no guarantee that the courts of any jurisdiction outside Ireland will respect the limitations on liability associated with segregated portfolio companies nor is there any guarantee that the creditors of one Fund will not seek to enforce such Fund's obligations against another Fund.

As at 31 December 2023 and 31 December 2022 there were no known contingent liabilities.

17. Soft Commission

There were no soft commissions for the financial year ended 31 December 2023 and 31 December 2022.

18. IMR Regulations

In response to the CBI publishing the Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) Investor Money Regulations 2015 for Fund Service Providers (the "Investor Money Regulations" or "IMR") issued in March 2015, subscription and redemption monies will (effective from 1 July 2016), be channeled through a sub-fund cash collection account in the name of the sub-fund. Pending issue of the shares and/or payment of subscription proceeds to an account in the name of the sub-fund(s), and pending payment of redemption proceeds or distributions, the relevant investor will be an unsecured creditor of the sub-fund in respect of amounts paid by or due to it. As at 31 December 2023 the Funds had no such amounts.

19. Comparative Year

The prior year comparatives are for the financial year 1 January 2022 to 31 December 2022.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value

The following tables outline the number of shares outstanding and the Net Asset Value per share for each share class for the last three reporting periods.

The transactions for the financial year ended 31 December 2023 are as follows:

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Total Net Asset Value	19,465,139	470,736,748
Shares outstanding		
Class A EUR	—	3,276
Class A NOK	—	72,267
Class A USD	—	22,809
Class B EUR	—	2,840
Class B NOK	—	227,181
Class B SEK	—	5,393
Class B USD	—	398,864
Class X EUR	—	222,392
Class X USD	—	173,198
Class E NOK	—	1,616,963
Class E USD	—	191,231
Class S GBP	54,752	—
Class S NOK	985,989	—
Class S USD	32,392	—
Class Y EUR	—	23,623
Class Y GBP	—	987,741
Class Y USD	—	585,302
Net Asset Value per Share		
Class A EUR	—	336.40
Class A NOK	—	3,054.07
Class A USD	—	527.22
Class B EUR	—	135.14
Class B NOK	—	1,581.60
Class B SEK	—	1,480.23
Class B USD	—	166.98
Class X EUR	—	107.93
Class X USD	—	182.79
Class E NOK	—	102.70
Class E USD	—	102.37
Class S GBP	99.50	—
Class S NOK	95.57	—
Class S USD	100.09	—
Class Y EUR	—	130.36
Class Y GBP	—	131.97
Class Y USD	—	117.71

The transactions for the financial year ended 31 December 2022 are as follows:

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Total Net Asset Value	—	533,513,347
Shares outstanding		
Class A EUR	—	17,009
Class A NOK	—	81,322
Class A USD	—	32,892
Class B EUR	—	2,840

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value (Continued)

The transactions for the financial year ended 31 December 2022 are as follows:

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Total Net Asset Value (continued)	–	533,513,347
Shares outstanding		
Class B NOK	–	444,096
Class B SEK	–	6,361
Class B USD	–	437,005
Class X EUR	–	309,159
Class X USD	–	235,820
Class E NOK	–	1,298,204
Class E USD	–	116,749
Class Y EUR	–	33,220
Class Y GBP	–	998,051
Class Y USD	–	563,795
Net Asset Value per Share		
Class A EUR	–	337.04
Class A NOK	–	3,049.87
Class A USD	–	518.75
Class B EUR	–	137.94
Class B NOK	–	1,612.07
Class B SEK	–	1,513.20
Class B USD	–	166.57
Class X EUR	–	108.53
Class X USD	–	179.46
Class E NOK	–	103.87
Class E USD	–	101.39
Class Y EUR	–	132.47
Class Y GBP	–	137.31
Class Y USD	–	115.56

The transactions for the financial year ended 31 December 2021 are as follows:

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Total Net Asset Value	–	480,884,750
Shares outstanding		
Class A EUR	–	19,729
Class A NOK	–	78,290
Class A USD	–	55,831
Class B EUR	–	2,840
Class B NOK	–	485,271
Class B SEK	–	16,855
Class B USD	–	283,700
Class X EUR	–	309,159
Class X USD	–	268,132
Class E NOK	–	306,725
Class E USD	–	73,494
Class Y EUR	–	38,054
Class Y GBP	–	657,122
Class Y USD	–	506,802

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

NOTES TO THE FINANCIAL STATEMENTS (Continued)

20. Three Year Historical Net Asset Value (Continued)

	Sector Emerging Markets Equities Fund USD	Sector Healthcare Value Fund USD
Net Asset Value per Share		
Class A EUR	—	349.87
Class A NOK	—	3,132.26
Class A USD	—	527.12
Class B EUR	—	144.51
Class B NOK	—	1,675.18
Class B SEK	—	1,586.41
Class B USD	—	169.79
Class X EUR	—	111.98
Class X USD	—	180.40
Class E NOK	—	107.21
Class E USD	—	102.57
Class Y EUR	—	124.71
Class Y GBP	—	122.32
Class Y USD	—	115.92

21. Significant Events during the financial year

On 13 April 2023, a supplement was noted by the Central Bank of Ireland for the new sub-fund Sector Emerging Markets Equities Fund, which launched on 1 September 2023.

There were no other significant events during the financial year.

22. Significant Events after the Balance Sheet Date

There were no significant events after the balance sheet date.

23. Approval of Financial Statements

The financial statements were authorised for issue by the Directors on 27 March 2024.

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited)

In accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 and the Central Bank (Supervision and Enforcement) Act 2013 (Section 48 (1) (Undertakings for Collective Investment in Transferable Securities) Regulations, 2019, a statement of the largest changes in the composition of the Schedule of Investments during the year is provided to ensure that the shareholders can identify changes in the investments held by the Fund. These statements present the aggregate purchases and sales of an investment, exceeding 1% of the total value of purchases and sales for the year. At a minimum the largest 20 purchases and sales are listed. If the Fund enters into less than 20 purchases or sales during the year, then all transactions are presented.

Sector Emerging Markets Equities Fund

LARGEST PURCHASES

	COST
Mobile World Investment Corp.	18,716,588
Phu Nhuan Jewelry JSC	15,214,752
Varun Beverages Ltd.	1,671,925
Taiwan Semiconductor Manufacturing Co. Ltd.	1,318,092
Central Depository Services Ltd.	1,205,063
PT Bank Central Asia Tbk	1,123,552
Titan Co. Ltd.	1,098,969
SBI Cards & Payment Services Ltd.	1,045,367
NU Holdings Ltd.	978,710
Cholamandalam Investment and Finance Co. Ltd.	972,767
Contemporary Amperex Technology Co. Ltd.	921,568
Jubilant FoodWorks Ltd.	915,232
Nvidia Corp.	887,368
Allkem Ltd.	847,615
Samsung SDI Co., Ltd.	832,969
Devyani International Ltd.	823,917
BYD Co. Ltd.	758,225
Sonata Software Ltd.	741,420
Indofood CBP Sukses (Indofood CBP)	708,944
Computer Age Management Services Ltd.	643,785

LARGEST SALES

	COST
	\$
Varun Beverages Limited	546,244
Central Depository Services Ltd.	545,758
Prosus N.V.	428,171
Allkem	403,196
Samsung SDI Co Ltd	385,373
Alibaba Group Holding Limited	347,203
Titan Co Ltd	343,756
Shenzhen Kedali Industry Co. Ltd.	323,179
LONGi Green Energy Technology Co. Ltd.	279,342
Taiwan Semiconductor Manufacturing Co. Ltd.	278,392
Contemporary Amperex Technology Co. Ltd.	276,342
LG Energy Solution	230,822
Sea Ltd.	217,610
PT Bank Central Asia Tbk	215,664
Jubilant FoodWorks	214,054
Cholamandalam Investment and Finance Co. Ltd.	200,919
Nvidia Corp.	199,488
Affle (India) Limited	195,680
Hangzhou First Pv Material Co., Ltd.	192,140
SBI Cards & Payment Services Limited	188,297

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

SIGNIFICANT PORTFOLIO MOVEMENTS (Unaudited)

Sector Healthcare Value Fund

LARGEST PURCHASES

	COST
	\$
Goldman Sachs US\$ Treasury Liquid Reserves Fund	38,139,644
Becton Dickinson & Co.	15,889,262
Baxter International, Inc.	14,466,705
Novartis AG	14,301,003
Biogen, Inc.	9,238,652
GE HealthCare	8,343,159
Catalent, Inc.	7,276,654
CVS Health Corp.	6,551,650
Bristol-Myers Squibb Co.	6,320,610
Otsuka Holdings Co. Ltd.	5,841,582
Biovitrum AB	5,747,329
Medtronic Plc	5,721,213
Eisai Co. Ltd.	5,657,279
Olympus Corp.	4,577,824
Johnson & Johnson	4,253,694
Amedisys, Inc.	4,143,023
Gilead Sciences, Inc.	3,912,984
Astellas Pharma, Inc.	3,901,511
Alnylam Pharmaceuticals, Inc.	3,377,746
Edwards Lifesciences Corp.	3,255,954

LARGEST SALES

	COST
	\$
Goldman Sachs US\$ Treasury Liquid Reserves Fund	49,394,615
Sanofi	19,994,279
Merck & Co., Inc.	17,075,896
Seagen, Inc.	14,272,721
Boston Scientific Corp.	11,080,210
CVS Health Corp.	9,874,718
Illumina, Inc.	8,861,611
Elevance Health Inc.	8,128,504
Baxter International, Inc.	7,196,269
the Cigna Group	6,961,288
Merck KGaA	6,366,691
Biogen, Inc.	5,944,729
Gilead Sciences, Inc.	5,886,088
Roche Holding AG	5,095,465
Bio-Rad Laboratories, Inc.	4,861,919
Bruker Corp.	4,250,041
Qiagen NV	4,160,449
GSK PLC	4,119,721
Astellas Pharma, Inc.	3,882,636
Terumo Corp.	3,831,300

SECTOR CAPITAL FUNDS PLC
Annual Report and Audited Financial Statements
For the financial year ended 31 December 2023

REMUNERATION INFORMATION (Unaudited)

Regulation 89(3A) of the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (S.I. No. 352 of 2011), as amended (the "UCITS Regulations") (as introduced pursuant to the European Union (Undertakings for Collective Investment in Transferable Securities) (Amendment) Regulations 2016 (the "UCITS V Regulations") on 21 March 2016) requires that the annual report of the Company contains certain disclosures on remuneration paid by the Company to its staff during the financial year and details of any material changes to the Company's remuneration policy made during the period.

In this regard, the following points are to be noted:

- The Company has prepared a remuneration policy outlining how it adheres to the remuneration requirements set out in the UCITS Regulations and ESMA's Guidelines on sound remuneration policies under the UCITS Directive (ESMA/2016/575) (the "Guidelines"). This policy was adopted with effect from 1 January 2018.
- No annual reviews have as yet been undertaken and no material changes have been made to the remuneration policy since 1 January 2020.

The Company has no employees or staff that it employs and pays directly. The Company has a Board of Directors, one of whom is an employee of the Sector group and receives no remuneration from the Company. The remaining two directors, each of whom is independent, receive a fixed fee only for the year ended 31 December 2023 EUR36,000 (31 December 2022: EUR36,000) in aggregate and do not receive variable remuneration. These fees are set at a level that reflects the qualifications and contribution required taking into account the Company's size, internal organisation and the nature, scope and complexity of its activities.

Periodic disclosure for the financial products referred to in Article 8, paragraphs 1, 2 and 2a, of Regulation (EU) 2019/2088 and Article 6, first paragraph, of Regulation (EU) 2020/852

Sustainable investment means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Product name: Sector Healthcare Value Fund (the "Fund")
Legal entity identifier: 635400AIUDDOVUMNJX04

Environmental and/or social characteristics

Did this financial product have a sustainable investment objective?	
☒ ☒ ☐ Yes ☐ It made sustainable investments with an environmental objective: ____% ☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy ☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy ☐ It made sustainable investments with a social objective: ____%	☒ ☐ ☒ No ☐ It promoted Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it had a proportion of ____% of sustainable investments ☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy ☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy ☐ with a social objective ☒ It promoted E/S characteristics, but did not make any sustainable investments

To what extent were the environmental and/or social characteristics promoted by this financial product met?

The following environmental and social characteristics were promoted by the Fund:

Environmental Characteristics

•Biodiversity and the environment

Social characteristics

- Ethical marketing and pricing practices
- Health and Safety
- Product Safety and Integrity

Performance in relation to these environmental and social characteristics was measured through the use of an exclusion list and third-party ESG data analysis.



How did the sustainability indicators perform?

As part of the investment process, the Investment Manager considered a variety of sustainability indicators to measure the environmental and social characteristics promoted by the Fund. These sustainability indicators are as follows:

(i) Exclusion List

To ensure that the environmental and social characteristics promoted by the Fund were attained, the Investment Manager applied specific investment exclusions when determining what investments to make as part of the portfolio construction.

The Investment Manager adhered to the Norges Bank observation and exclusion of companies list (the "**Exclusion List**"), ensuring that the Fund did not invest in companies in contravention of the Exclusion List. The Exclusion list can be found at <https://www.nbim.no/en/the-fund/responsible-investment/exclusion-of-companies>

(ii) Third-party ESG data analysis

In addition to integrating the aforementioned Exclusion List into the portfolio construction process, the Investment Manager measured portfolio companies using information provided by a third-party ESG data provider which allocated a specific ESG rating to company holdings in the Fund and investee companies that the Investment Manager was looking at as potential investments (the "**ESG Rating**").

Investee companies were assigned a value creation score where the company's resilience to long-term industry material environmental, social and governance risks forms part of the value score through the use of third party ESG ratings. Industry ESG leaders were positively impacted, whereas laggards were negatively impacted in the Investment Manager's value creation score.

This ESG Rating measured an investee company's resilience to long-term industry material environmental, social and governance risks. A rules-based methodology was used to identify companies that are (i) industry leaders (ii) average or (iii) laggards, according to their exposure to ESG risks and how well they manage those risks relative to peers.

The Investment Manager also tracked and reported on the performance of the above sustainability indicators namely, (i) the adherence to the Exclusion List applied to the Fund; and (ii) the ESG Rating.

These sustainability indicators were used to measure the attainment of each of the environmental and social characteristics promoted by the Fund.


The table below shows the weighted performance for the positions held in the Fund by the ESG Rating for the reference period.

Rating	Sector Healthcare Value Fund	
	Weight	Return
AAA	7.5%	15.0%
AA	33.9%	0.5%
A	30.3%	-2.7%
BBB	11.5%	7.1%
BB	1.0%	11.1%
Not Classified	15.8%	9.25%

and compared to previous periods?

Compared to previous period, portfolio exposure to AAA, AA-rated companies has increased. The Investment Manager has seen the increasing amount of companies disclosing their sustainability information and thus being rated by third-party vendors and research providers. The Investment Manager recognizes the importance of reliable, consistent, and comparable information regarding various sustainability factors which can enable the team to price sustainability risk correctly. The Investment Manager assesses the quality of all external data on an ongoing basis.

Portfolio ESG distribution difference from last year



The Investment Manager believes the ESG ratings had limited impact on the performance. Weight of the «Not Classified» category was up compared to previous period due to two major spin-out from General Electric and Novartis, which have not been ESG-rated by the major ratings agencies by the end of the reporting period. Due to the size of the companies and the requirements from the regulators to sustainability reporting and transparency, the Investment Manager expects those companies to be rated shortly.

What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objectives?

N/A – the Fund did not make any sustainable investments in the reporting period.

How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?

N/A – the Fund did not make any sustainable investments in the reporting period.

How were the indicators for adverse impacts on sustainability factors taken into account?

N/A

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

N/A - the Fund did not make any sustainable investments in the reporting period.

The EU Taxonomy sets out a “do not significant harm” principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The “do no significant harm” principle applies only to those investments underlying the financial product that take into account the EU criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



How did this financial product consider principal adverse impacts on sustainability factors?

N/A – the Investment Manager did not consider PAIs with respect to the Fund.



What were the top investments of this financial product?

	Sector	% Assets	Country
GSK PLC	Healthcare	7.3	BRITAIN
MEDTRONIC PLC	Healthcare	5.2	IRELAND
GILEAD SCIENCES INC	Healthcare	4.7	UNITED STATES
PFIZER INC	Healthcare	4.5	UNITED STATES
BIOGEN INC	Healthcare	3.8	UNITED STATES
SANOFI	Healthcare	3.7	FRANCE
INCYTE CORP	Healthcare	3.7	UNITED STATES
NOVARTIS AG-REG	Healthcare	3.5	SWITZERLAND
BRISTOL-MYERS SQUIBB CO	Healthcare	3.1	UNITED STATES
OTSUKA HOLDINGS CO LTD	Healthcare	3.1	JAPAN
GE HEALTHCARE TECHNOLOG-W/I	Healthcare	2.8	UNITED STATES
UCB SA	Healthcare	2.8	BELGIUM
CVS HEALTH CORP	Healthcare	2.6	UNITED STATES
ZIMMER BIOMET HOLDINGS INC	Healthcare	2.6	UNITED STATES
CARDINAL HEALTH INC	Healthcare	2.5	UNITED STATES



The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is: 29/12/2023

What was the proportion of sustainability-related investments?

● What was the asset allocation?

The proportion of investments aligned with the environmental and social characteristics promoted by the Fund was 84.2% during the reference period.


To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

A company was considered aligned with the environmental and social characteristics of the Fund if the company was not on the aforementioned exclusion list and if the Investment Manager was able to obtain the third party ESG-rating. The ESG-rating impacted the portfolio weight by punishing laggards and rewarding winners in our scorecard model which was used as input to the Funds investment portfolio process.

The Fund aimed to hold a minimum of 80% investments that were aligned with the environmental or social characteristics promoted by the Fund.



In which economic sectors were the investments made?

Data as of 31 December 2023	
GICS	% Assets
Healthcare	97.2
Cash	2.8



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

N/A – the Fund did not commit to holding Taxonomy-aligned investments.

- Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy¹?

☐ Yes:



In fossil gas





In nuclear energy

☒ No

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.*

N/A – the Fund did not commit to holding Taxonomy-aligned investments.



- What was the share of investments made in transitional and enabling activities?

N/A – the Fund did not commit to holding Taxonomy-aligned investments.

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change (“climate change mitigation”) and do not significantly harm any EU Taxonomy objective - see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

- **How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?**

N/A – the Fund did not commit to holding Taxonomy-aligned investments.



What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy?

N/A – the Fund did not commit to holding sustainable investments with an environmental objective not aligned with the EU-Taxonomy.



What was the share of socially sustainable investments?

N/A – the Fund did not commit to holding socially sustainable investments.



What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

“Other” included the remaining investments of the Fund which were neither aligned with the environmental or social characteristics, nor qualified as sustainable investments. This “Other” section in the Fund included companies that were not well covered by third party ESG rating agencies, thereby reducing the Investment Manager's visibility on ESG matters in respect of these companies. Typically newer and smaller market capitalization companies fall into this category.

The “Other” section in the Fund also included cash that was held for a number of reasons that the Investment Manager felt was beneficial to the Fund, such as, but not limited to, achieving risk management, and/or to ensure adequate liquidity and hedging.

A lack of disclosure and visibility on ESG matters impacted the capital allocation towards this “Other” segment but the investee companies that comprise the “Other” were not strictly excluded from the Fund as the Investment Manager believed there were mis-pricings that could be capitalised on within this segment.

As noted above, the Fund was invested in compliance with the Exclusion List, on a continuous basis. The Investment Manager believes that compliance with the Exclusion List prevents investments in companies that breach environmental and/or social minimum standards and ensures that the Fund can successfully promote its environmental and social characteristics. By adhering to the Exclusion List, the Investment Manager ensured that robust environmental and social safeguards were in place.



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

The Fund was managed in-line with the investment objective and the following actions were taken:

(i) Exclusion List:

To ensure that the environmental and social characteristics promoted by the Fund were attained, the Fund applied the Exclusion List referenced above, which placed limitations on the investable universe.

(ii) Integrating third-party ESG analysis:

In addition to integrating the aforementioned Exclusion List into the portfolio construction process, the Investment Manager measured all portfolio companies using the aforementioned ESG Rating. The ESG Rating was used to measure the environmental and social characteristics promoted by the Fund.

As noted above, this ESG Rating was designed to measure an investee company's resilience to long-term industry material environmental, social and governance risks. A rules-based methodology was used to identify companies that were (i) industry leaders (ii) average or (iii) laggards, according to their exposure to ESG risks and how well they manage those risks relative to peers.

Investee companies were assigned a value creation score where the company's resilience to long-term industry material environmental, social and governance risks forms part of the value score through the use of third party ESG ratings. Industry ESG leaders were positively impacted, whereas laggards were negatively impacted in the Investment Manager's value creation score.



How did *this financial product* perform compared to the reference benchmark?

N/A – the Fund did not designate a reference benchmark the purpose of attaining the environmental or social characteristics promoted.

● ***How does the reference benchmark differ from a broad market index?***

N/A

● ***How did this financial product perform with regard to the sustainability indicators to determine the alignment of the reference benchmark with the environmental or social characteristics promoted?***

N/A

● ***How did this financial product perform compared with the reference benchmark?***

N/A

● ***How did this financial product perform compared with the broad market index?***

N/A

Reference benchmarks are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.